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Summary of findings {#CD009913-sec1-0001}
===================

Summary of findings for the main comparison\'Summary of findings\' table 1Fixed‐dose combinations compared to single‐drug formulations for treating newly diagnosed pulmonary tuberculosis (TB)**Participant or population:** treating pulmonary TB **Setting:** hospitals and health centres for TB treatment **Intervention:** fixed‐dose combinations **Comparison:** single‐drug formulations**OutcomesIllustrative comparative risks^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Quality of the evidence (GRADE)Assumed risk**\
**single‐drug formulationsCorresponding risk**\
**FDCs**Treatment failure19 per 100024 per 1000 (15 to 37)RR 1.28 (0.82 to 2.00)3606 (7 RCTs)⊕⊕⊕⊝ moderate^1,2,3,4^Relapse55 per 100071 per 1000 (55 to 91)RR 1.28 (1.00 to 1.64)3621 (10 RCTs)⊕⊕⊝⊝ low^2,3,4,5^Death25 per 100024 per 1000 (17 to 34)RR 0.96 (0.67 to 1.39)4800 (11 RCTs)⊕⊕⊕⊝ moderate^1,3,6,7^Sputum smear or culture conversion at end of treatment892 per 1000883 per 1000 (857 to 910)RR 0.99 (0.96 to 1.02)2319 (7 RCTs)⊕⊕⊕⊕ high^1,2,3,8^Serious adverse events16 per 100023 per 1000 (14 to 37)RR 1.45 (0.90 to 2.33)3388 (6 RCTs)⊕⊕⊕⊝ moderate^1,2,3,7^Adverse events leading to discontinuation of therapy40 per 100038 per 1000 (22 to 67)RR 0.96 (0.56 to 1.66)5530 (13 RCTs)⊕⊕⊝⊝ low^3,4,5,9^Combined endpoint of treatment failure, relapse, or death\*\*---------(0 RCTs)---\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). \*\*Outcome not reported. **Abbreviations:** CI: confidence interval; RR: risk ratio; TB: tuberculosis; FDCs: fixed‐dose combinations; RCTs: randomized controlled trial.**GRADE Working Group grades of evidence** **High quality:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. **Very low quality:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.[^2]

Background {#CD009913-sec1-0002}
==========

Description of the condition {#CD009913-sec2-0001}
----------------------------

Tuberculosis (TB) is a global pandemic and the disease caused approximately nine million new cases and 1.5 million deaths in 2014. It is a major public health problem and is one of the infectious diseases with the highest incidence in the world. It is caused by bacterial species of the *Mycobacterium tuberculosis* complex (a genetically closely‐related group of *Mycobacterium* species). TB most commonly affects the lungs (pulmonary TB), although it can also affect other organs and systems (extrapulmonary TB). It is transmitted from person to person by droplets from the throat and lungs of people with active respiratory TB. The most common symptom of pulmonary TB is a persistent and productive cough, sometimes with haemoptysis (expulsion of sputum with blood). It is often accompanied by general symptoms such as fever, night sweats, and weight loss. The symptoms for extrapulmonary TB depend on the site of disease, and are usually accompanied by intermittent fever and weight loss. Anyone can contract TB, but people with prolonged and close household exposure to a person with active pulmonary TB are at greatest risk. The probability of developing TB is much higher among people infected with human immunodeficiency virus (HIV). TB is also more common among men than women, and affects mostly adults in the economically productive age groups. Accurate and early diagnosis, in addition to rapid and appropriate treatment, are the most important actions in TB care and control ([@CD009913-bbs2-0045]; [@CD009913-bbs2-0047]; [@CD009913-bbs2-0060]).

### Treatment of tuberculosis {#CD009913-sec3-0001}

Effective treatment that ensures a rapid and lasting cure is the main component in TB control. *M. tuberculosis* is a slow‐growing bacillus and treatment requires multiple drugs over a prolonged time period. The ultimate objective is to cure the disease and prevent drug resistance developing. The recommended oral drugs for first‐line anti‐TB treatment are isoniazid (H), rifampicin (R), pyrazinamide (Z), and ethambutol (E). The standard short‐course TB treatment for new patients with pulmonary TB consists of six months of rifampicin‐based regimen (2HRZE/4HR), given daily or three times per week. There are some considerations to take into account in TB treatment. Pulmonary and extrapulmonary disease should be treated with the same regimen, but in some cases of extrapulmonary TB (such as TB meningitis and bone or joint TB) the recommended therapy is longer than the standard TB regimen. Ideally, drug regimens for all patients should depend on the results of drug susceptibility testing to guide the therapy ([@CD009913-bbs2-0045]; [@CD009913-bbs2-0048]; [@CD009913-bbs2-0056]; [@CD009913-bbs2-0059]).

The recommended doses for treatment of children with TB differ compared to treatment of adults. Correct treatment prescription for children with TB remains a challenge. Current guidance of the World Health Organization (WHO) for the treatment of children with TB is based on the last scientific evidence and recommends the use of fixed‐dose combinations (FDCs) ([@CD009913-bbs2-0055]; [@CD009913-bbs2-0059]). Nevertheless, currently available FDCs on the market for TB treatment do not correspond with the appropriate doses for children, making treatment very difficult or unfeasible.

Assessment and promotion of treatment adherence is critical for the achievement of favourable patient outcomes, and directly observed treatment (DOT) and training for a treatment supporter (parent or responsible adult for supervised treatment) are recommended strategies when addressing this issue ([@CD009913-bbs2-0045]; [@CD009913-bbs2-0056]; [@CD009913-bbs2-0059]).

Description of the intervention {#CD009913-sec2-0002}
-------------------------------

FDCs are pills that contain more than one active ingredient. Anti‐TB drugs may contain two, three, or four active ingredients in one tablet. Pharmacokinetic studies of anti‐TB drugs show that absorption, plasma concentrations, and others pharmacokinetic parameters are similar for FDCs and single‐drug formulations ([@CD009913-bbs2-0037]; [@CD009913-bbs2-0062]). FDCs appear on the WHO Model List of Essential Medicines ([@CD009913-bbs2-0057]). Both the WHO, [@CD009913-bbs2-0056], and the International Standards for Tuberculosis Care, [@CD009913-bbs2-0045], recommend the use of FDCs for standard TB treatment regimens. The national TB programmes of most high‐burden TB countries have adopted FDCs as standard TB treatment regimens ([@CD009913-bbs2-0053]).

How the intervention might work {#CD009913-sec2-0003}
-------------------------------

The increase in drug resistance amongst species of the *M. tuberculosis* complex has become a critical issue in global TB control. With the use of single‐drug formulations the treatment adherence could be lower, the patient could choose to stop using one or more drugs (perceived by them as problematic in terms of side effects) while continuing use of the other drugs, or some patients may interrupt treatment completely. This may lead to the selection of drug‐resistant *M. tuberculosis* strains.

The main reasons for the use of FDCs are the improvement in treatment adherence and reduced rates of drug resistance ([Figure 1](#CD009913-fig-0001){ref-type="fig"}). By using FDCs the number of pills to be taken by the patient is considerably reduced ([@CD009913-bbs2-0045]), making it possible to increase patient satisfaction and decrease medication errors, burden, and cost for patients. Prescription mistakes may be lowered and the efficiency in the drug supply system may be increased due to fewer drug orders and shipments ([@CD009913-bbs2-0040]; [@CD009913-bbs2-0041]; [@CD009913-bbs2-0051]). The major advantages of using FDCs to treat people with TB are simplified treatment and drug management and decreased probability of monotherapy ([@CD009913-bbs2-0040]). Moreover, FDCs tend to improve adherence in various settings ([@CD009913-bbs2-0042]).Figure 1Logic diagram of relationship between the use of fixed‐dose combinations (FDCs) and expected improvement of reported outcomes.

There are some disadvantages to the use of FDCs. It may be difficult to identify the relationship between an adverse drug reaction and one of the components of FDCs if any toxicity issues occur. In addition, FDCs may impede further dose adjustments. Another disadvantage of FDCs is poor rifampicin bioavailability if strict manufacturing procedures are not followed or poor quality materials are used ([@CD009913-bbs2-0040]).

Why it is important to do this review {#CD009913-sec2-0004}
-------------------------------------

The effectiveness of FDCs has been tested in randomized controlled clinical trials, but small sample sizes and differences in treatment doses or schedule have limited the applicability of their results. This Cochrane review on the effectiveness of FDCs versus single‐drug formulations for the treatment of pulmonary TB will help to evaluate the benefits and disadvantages of FDCs based on the existing scientific evidence.

Objectives {#CD009913-sec1-0003}
==========

To compare the efficacy, safety, and acceptability of anti‐tuberculosis regimens given as fixed‐dose combinations compared to single‐drug formulations for treating people with newly diagnosed pulmonary tuberculosis.

Methods {#CD009913-sec1-0004}
=======

Criteria for considering studies for this review {#CD009913-sec2-0005}
------------------------------------------------

### Types of studies {#CD009913-sec3-0002}

Randomized controlled trials (RCTs).

### Types of participants {#CD009913-sec3-0003}

Male and female adolescents and adults (aged 15 years or older), newly diagnosed with pulmonary TB, confirmed by sputum smear or culture, or both, or according to the World Health Organization (WHO) definition for a case of tuberculosis (TB): participants in which a health worker has diagnosed TB and has decided to treat with a full course of TB treatment ([@CD009913-bbs2-0056]).

We excluded children, people with extrapulmonary TB, and those previously treated for TB. We excluded children due to difficulties in childhood TB treatment with the available fixed‐dose combinations (FDCs) ([@CD009913-bbs2-0055]; [@CD009913-bbs2-0059]).

We excluded studies that included both adults and children, unless subgroup data for adults were available from the study report.

### Types of interventions {#CD009913-sec3-0004}

#### Intervention {#CD009913-sec4-0001}

FDC chemotherapy.

#### Control {#CD009913-sec4-0002}

Multiple single‐drug formulation chemotherapy.

For all included trials, the intervention and control groups had to use the same components and dose schedule. We included trials in which TB treatment was administered for a minimum of two months, but did not exceed nine months.

### Types of outcome measures {#CD009913-sec3-0005}

#### Primary outcomes {#CD009913-sec4-0003}

A combined endpoint of treatment failure, relapse, or death.Treatment failure.Relapse.Death.

We reported death due to any cause.

#### Secondary outcomes {#CD009913-sec4-0004}

Sputum smear or culture conversion.Time to sputum smear or culture conversion.Time to relapse.Treatment adherence (as defined by the trial authors).Acquisition of drug resistance (as defined by the trial authors).Patient satisfaction characterized as:general satisfaction;no problems swallowing;acceptable taste.Adverse events characterized as:serious (death, hospitalizations);those leading to discontinuation of therapy;other adverse events.

For sputum smear or culture conversion we took culture conversion data instead of sputum smear data when both were available. We assessed dichotomous outcomes at two to three months, at the end of treatment (EOT), and at follow‐up when data were available. For treatment adherence and acquisition of drug resistance, we used the definitions suggested by the trial authors (see [Table 9](#CD009913-tbl-0009){ref-type="table"}).Table 1Suggested definitions of main outcomes according to the authors of included trials**Trial^1^Outcomes^2^DefinitionsNotes**[@CD009913-bbs2-0001]Treatment failure"sputum smear still or again positive after 4 and/or 6 months of treatment"Treatment efficacy based on bacteriological response rate (sputum smear conversion rate) on 2 smearsRelapse"patient cured at end of treatment (EOT) and sputum smear again positive at months 9 or 12"[@CD009913-bbs2-0002]Treatment failure"two positive cultures with or without radiological deterioration at EOT (treatment failure) or during the follow‐up (relapse) and consequently resulting in a new course of treatment"Treatment efficacy based on bacteriological criteria (2 negative cultures)RelapseTreatment adherenceNot definedDetermined by testing urine for isoniazid metabolites by biochemical methodsAcquisition of drug resistanceDetermined by drug sensitivity test for isoniazid, rifampicin and streptomycin[@CD009913-bbs2-0003]Treatment adherenceNot definedAsking patients for missed doses, by pill counts and by testing urine for isoniazid metabolites[@CD009913-bbs2-0004]Treatment failure"One culture of at least 20 colonies\` growth or 2 cultures of 10 or more colonies growth at EOT not identified as a reinfection"Treatment efficacy based on bacteriological results: 2 sputum smears and cultures. One case of relapse was reported based only in radiologic deteriorationRelapse"One culture of at least 20 colonies\` growth or 2 cultures of 10 or more colonies growth in the follow‐phase not identified as reinfection"Acquisition of drug resistanceNot definedDetermined by drug sensitivity test for isoniazid, rifampicin, streptomycin and ethambutol[@CD009913-bbs2-0006]RelapseNot definedEfficacy based on bacteriological results (sputum smear and culture)Treatment adherenceNot definedAssessed by delay in drug collection and surprise pill counting[@CD009913-bbs2-0008]Treatment failureNot definedTreatment efficacy based on clinical, bacteriological (3 sputum smears and cultures) and radiographic criteriaRelapseEfficacy based on bacteriological results (3 sputum smears and cultures)Treatment adherenceAssessed by "cases lost to follow‐up and cases who changed to another regimen during treatment"[@CD009913-bbs2-0009]Treatment failure\"Smear positive at 5 months or later\"^3^Efficacy based on bacteriological results (sputum smear)Relapse"Definite TB relapse: a patient previously declared cured with a new episode of bacteriologically positive TB by sputum smear microscopy or culture.Possible TB relapse, based on interviews, proxy interviews or verbal autopsies: a patient previously declared cured with a history of recurrent signs and symptoms of TB, a history of sputum examination after cure and a history of being treated for TB after cure, or a patient previously declared cured who died with signs and symptoms consistent with or suspected of TB".Efficacy based on bacteriological results (1 smear sputum and culture) and information from interviews and verbal autopsies[@CD009913-bbs2-0010]Treatment failureNot definedTreatment efficacy based on bacteriological results (sputum smear and culture)Relapse"Bacteriological relapse after chemotherapy was defined as a positive culture with a growth of 10 or more colonies in 2 different months during any 3‐month period up to 30 months, and during any 6‐month period up to 60 months"Efficacy based on bacteriological results (sputum smear and culture). One case of relapse was reported based on radiological deteriorationAcquisition of drug resistanceNot definedDetermined by drug sensitivity test for isoniazid, rifampicin, and streptomycin[@CD009913-bbs2-0012]RelapseNot definedEfficacy based on bacteriological results (sputum smear)[@CD009913-bbs2-0013]RelapseNot definedEfficacy based on bacteriological results (sputum smear and culture)[@CD009913-bbs2-0014]Treatment adherenceNot definedThere were 3 kinds of treatment management (whole‐course hospitalization; hospitalization only during intensive phase and outpatient treatment), combined with 3 supervision model respectively (supervision by medical staff; supervision by no‐medical staff who had been trained by the medical staff \[relatives, colleagues\] and supervision by medical staff in the intensive phase but non‐medical staff in the continuation phase). Treatment and supervision were established according to participants economic status[^3]

Search methods for identification of studies {#CD009913-sec2-0006}
--------------------------------------------

We searched for all relevant trials regardless of language or publication status (published, unpublished, in press, and ongoing).

### Electronic searches {#CD009913-sec3-0006}

We searched the following databases: the Cochrane Infectious Disease Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL, published in the Cochrane Library, Issue 11 2015); MEDLINE (1966 to 20 November 2015); EMBASE (1980 to 20 November 2015); and LILACS (1982 to 20 November 2015), using the search terms detailed in [Appendix 1](#CD009913-sec2-0016){ref-type="app"}. We also searched the metaRegister of Controlled Trials (mRCT) (20 November 2015) and the search portal of the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) ([www.who.int/trialsearch](www.who.int/trialsearch)) (20 November 2015), to identify ongoing trials, using  "tuberculosis" and "fixed dose OR combination" as search terms.

### Searching other resources {#CD009913-sec3-0007}

We contacted trial authors in the field to identify additional studies that may have met the inclusion criteria. We checked projects of relevant organizations, including the WHO, the Tuberculosis Trials Consortium (TBTC), the International Union Against Tuberculosis and Lung Disease, and the WHO Global TB Programme to identify any unpublished and ongoing trials.

We also checked the reference lists of all relevant studies identified by the above methods.

Data collection and analysis {#CD009913-sec2-0007}
----------------------------

### Selection of studies {#CD009913-sec3-0008}

Two review authors (CRG and AVR) independently screened the titles and abstracts of all citations retrieved by the search to identify potentially eligible studies. We obtained the full‐text articles of potentially eligible studies and independently evaluated these studies for inclusion in the review, based on the inclusion and exclusion criteria. When we found multiple publications for the same study, we ensured that we counted these as the same study. In case of disagreements, we consulted a third review author (DRC) to resolve them. We documented the reasons for exclusion of studies.

### Data extraction and management {#CD009913-sec3-0009}

Two review authors (CRG and AVR) independently extracted data from the included trials using a standardized data extraction sheet. For all included trials, we extracted information regarding the number of randomized participants and the number of participants whose outcomes were measured. We extracted the number of events and the number of participants assessed in each treatment arm for dichotomous outcomes. For continuous outcomes, we extracted the arithmetic means and standard deviations, together with the number of participants in each group. We resolved discrepancies regarding the extracted data with another two review authors (MRF and DRC) when necessary. When we required additional details, we contacted the trial authors by email.

For all included trials we extracted the following information when available.

Trial details: publication details, study design, methodological criteria, country and trial setting (hospital or clinic).Participant characteristics: age, gender, inclusion and exclusion criteria, sputum smear status if available, mycobacterial culture data, baseline drug susceptibility testing, and HIV status.TB treatment details: types of regimen, dosage, frequency (daily or intermittent), mode of administration (self‐administered or supervised treatment), duration of follow‐up, withdrawal, and loss to follow‐up.Outcome details (see the \'[Types of outcome measures](#CD009913-sec3-0005){ref-type="sec"}\' section).

### Assessment of risk of bias in included studies {#CD009913-sec3-0010}

Two review authors (CRG and AVR) independently assessed the risk of bias in the included trials using a standardized assessment form. In case of disagreement, we consulted a third review author (DRC). We assessed the following six components in each included trial: sequence generation; allocation concealment; blinding (study participants, investigators, and outcome assessors); incomplete outcome data; selective outcome reporting; and other sources of bias. For each of these components, we assigned a judgment regarding the risk of bias of either \'low\', \'high\', or \'unclear\' (if insufficient detail was reported, or insufficient information was provided and the risk of bias was unknown) ([@CD009913-bbs2-0044]). We recorded the results in the standard \'Risk of bias\' table in Review Manager (RevMan) ([@CD009913-bbs2-0050]), and summarized the findings in a \'Risk of bias\' table and \'Risk of bias\' graph.

### Measures of treatment effect {#CD009913-sec3-0011}

We analysed the effect of treatment for dichotomous outcomes using the risk ratio (RR) and 95% confidence interval (CI). For continuous data, we planned to measure the effect of treatment with differences in means and their 95% CIs. We planned to assess the effect of treatment for time‐to‐event measures with hazard ratios (HRs) and their 95% CIs.

### Dealing with missing data {#CD009913-sec3-0012}

For the main analysis, we did not take missing data into account and presented the data as \"available data\" according to data given in the original trials for all outcomes (see [Data and analyses](#CD009913-sec1-0011){ref-type="sec"}: Comparison 1 \'Fixed‐dose combinations versus single‐drug formulations as available data\'). The same approach was taken for the sensitivity analysis that considered the \'Risk of bias\' assessment of included trials (see [Data and analyses](#CD009913-sec1-0011){ref-type="sec"}: Comparison 2 \'Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias\').

We performed a sensitivity analysis using an intention‐to‐treat (ITT) approach for the primary and secondary dichotomous outcomes relating to treatment efficacy (treatment failure, relapse, and sputum smear or culture conversion at 2 months or end of treatment). See [Data and analyses](#CD009913-sec1-0011){ref-type="sec"}: Comparison 3 \'Fixed‐dose combinations versus single‐drug formulations: sensitivity analysis by intention‐to‐treat (ITT)\'. The ITT sensitivity analyses were performed under the hypothesis that all participants lost during follow‐up presented negative events for the considered outcomes. We didn\'t perform a similar sensitivity analysis for death, because any hypothesis regarding participants lost to follow‐up seemed unreasonable.

### Assessment of heterogeneity {#CD009913-sec3-0013}

We assessed heterogeneity among trials by visual inspection of forest plots, application of the Chi² test with a 10% level of statistical significance, and consideration of the I² statistic. We used an I² statistic value of 50% to denote moderate heterogeneity and 75% or greater to denote substantial heterogeneity.

### Assessment of reporting biases {#CD009913-sec3-0014}

We assessed the likelihood of small study effects, such as publication bias, by visual examination of the funnel plot for asymmetry when there where at least 10 included trials.

### Data synthesis {#CD009913-sec3-0015}

We calculated a pooled estimate of treatment using a fixed‐effects model when minimal heterogeneity was present and a random‐effects model when moderate heterogeneity was present. We did not attempt to perform a meta‐analysis if the I² statistic value was greater than 75%.

For the main analysis, we presented an \"available case analysis\" according to data presented in the original trials for all outcomes (see [Data and analyses](#CD009913-sec1-0011){ref-type="sec"}: Comparison 1 \'Fixed‐dose combinations versus single‐drug formulations as available data\').

We pooled trial data for continuous or dichotomous outcomes with the Mantel‐Haenzel method. If HRs had been available for time‐to‐event data, we would have pooled them with the inverse‐variance method.

We performed statistical analyses using RevMan ([@CD009913-bbs2-0050]) and presented the results with 95% CIs.

We assessed the quality of the evidence using the Grading of Recommendations Assessment, Evaluation and Development (GRADE) approach. We summarized the quality of evidence for the main outcomes and the RCT data in \'Summary of findings\' tables. We constructed the \'Summary of findings\' tables using GRADEpro Guideline Development Tool (GDT) software (available from www.gradepro.org).

### Subgroup analysis and investigation of heterogeneity {#CD009913-sec3-0016}

We explored potential sources of heterogeneity by analysing the following subgroups.

FDCs administered only during the intensive phase versus FDCs administered for the whole treatment.Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase.Supervised treatment versus self‐administered treatment during the intensive phase.Trials with four drugs as FDCs versus trials with three or two drugs as FDCs during the intensive phase.HIV‐positive participants versus HIV‐negative participants.Clinically diagnosed participants versus laboratory diagnosed participants.

For the subgroup analysis we presented an \'available case analysis\'.

### Sensitivity analysis {#CD009913-sec3-0017}

We performed the following sensitivity analyses.

We conducted a sensitivity analysis to explore the impact of the \'Risk of bias\' assessment on the main analysis. We analysed separately the two trials at low risk of selection bias ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0004]) (see [Data and analyses](#CD009913-sec1-0011){ref-type="sec"}: Comparison 2 \'Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias\').We performed a sensitivity analysis to explore the impact of missing data on the main analysis, for primary and secondary dichotomous outcomes related to treatment efficacy. We conducted this analysis as an ITT analysis. We kept participants in the intervention groups to which they were randomized, regardless of the intervention to which they ended the follow‐up, and included all randomized participants in the analysis. We imputed missing data for patients lost to follow‐up under the hypothesis that all of them presented negative events (see [Data and analyses](#CD009913-sec1-0011){ref-type="sec"}: Comparison 3 \'Fixed‐dose combinations versus single‐drug formulations: sensitivity analysis by intention‐to‐treat).

Results {#CD009913-sec1-0005}
=======

Description of studies {#CD009913-sec2-0008}
----------------------

See the \'[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\' and \'[Characteristics of excluded studies](#CD009913-sec2-0020){ref-type="sec"}\' sections.

### Results of the search {#CD009913-sec3-0018}

We retrieved 619 records, of which we selected 50 as potentially relevant after we screened the title and abstract. After we excluded four further articles, we assessed the full text of 46 articles and 14 trials met the inclusion criteria. We included 13 trials in the meta‐analysis. We illustrated the selection process in a flow diagram (see [Figure 2](#CD009913-fig-0002){ref-type="fig"}).Figure 2Flow diagram of the trial selection process.

Among the potentially relevant records, we retrieved one unpublished trial that met the inclusion criteria ([@CD009913-bbs2-0025]). We also retrieved four studies that were not yet classified (see the \'[Characteristics of studies awaiting classification](#CD009913-sec2-0021){ref-type="sec"}\' section).

### Included studies {#CD009913-sec3-0019}

#### Included studies {#CD009913-sec4-0005}

In the qualitative synthesis, we included 14 RCTs, published between 1987 and 2015, that compared the use of fixed‐dose combinations (FDCs) versus single‐drug formulations to treat participants with newly diagnosed pulmonary tuberculosis (TB). We included 13 trials in the meta‐analysis. All but one trial, [@CD009913-bbs2-0009], described the follow‐up duration, and ranged from four months to five years after initiation of treatment. We have described details of the 14 trials in the \'[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\' section.

#### Participants {#CD009913-sec4-0006}

We included 14 trials in the qualitative analysis which included 6211 randomized participants. The meta‐analysis included 13 RCTs with 5824 randomized participants, with a range of 40 to 1585 participants per trial (see [Table 10](#CD009913-tbl-0010){ref-type="table"}). All participants were 15 years of age or older. The proportion of male participants ranged between 27.8% and 88.6% across the included trials.Table 2Numbers of randomized participants and treatment regimens of trials included in the meta‐analysis**TrialNumber of participantsTreatment regimens**[@CD009913-bbs2-0001]11592HRZE/4HR[@CD009913-bbs2-0002]2502HRZ/4HR[@CD009913-bbs2-0003]7012HRZ/4HR[@CD009913-bbs2-0004]15852HRZE/4HR^1^[@CD009913-bbs2-0005]402HRZE/4HR[@CD009913-bbs2-0006]2292HRZ/4HR^1^[@CD009913-bbs2-0008]1052HRZE/4HRE[@CD009913-bbs2-0009]4342HRZE/3HR[@CD009913-bbs2-0010]3103 different regimes were given^2^[@CD009913-bbs2-0011]1612HRZE/4HRE[@CD009913-bbs2-0012]2932HRZE/4HRE[@CD009913-bbs2-0013]2092HRZ/4HR[@CD009913-bbs2-0014]3482HRZ/4HR[^4]

All trials included participants with pulmonary TB whose status had been confirmed by microbiological diagnosis (sputum smear or culture, or both). Only two included trials described the HIV status of the participants ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0004]).

#### Location and setting {#CD009913-sec4-0007}

Most included trials were conducted in high TB‐burden countries, or low‐ and middle‐income countries, or both (see the \'[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\' section).

The RCTs were conducted in different continents and countries. Eight trials were conducted in Asia ([@CD009913-bbs2-0006]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0009]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0012]; [@CD009913-bbs2-0013]; [@CD009913-bbs2-0014]), two in Europe ([@CD009913-bbs2-0005]; [@CD009913-bbs2-0007]), one in Africa ([@CD009913-bbs2-0002]), and one in the USA ([@CD009913-bbs2-0003]). Two trials involved several countries ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0004]). All trials but two ([@CD009913-bbs2-0001] and [@CD009913-bbs2-0008]) gave details of the trial setting: hospital (six trials), clinics (four trials), hospital and health centre (one trial), and a different setting in each included country (one trial). We have provided the details of the country where each trial was conducted in \"[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\".

#### Interventions {#CD009913-sec4-0008}

All but three included trials, [@CD009913-bbs2-0004], [@CD009913-bbs2-0006], and [@CD009913-bbs2-0007], used a six‐month treatment regimen. [@CD009913-bbs2-0004] and [@CD009913-bbs2-0006] used a 26‐week regimen, and [@CD009913-bbs2-0007] employed a four‐month regimen (see [Table 10](#CD009913-tbl-0010){ref-type="table"}).

Although all included RCTs compared FDCs versus single‐drug formulations for treatment of pulmonary TB in newly diagnosed participants and used the same drugs and a comparable dose schedule in the intervention and control group, there were some differences in treatment administration between trials.

We included trials which gave drugs for a minimum of two months, but did not exceed nine months. We included one trial, [@CD009913-bbs2-0010], where 33% of the participants received drugs for the intensive phase for only a month, and for two months in the case of the remaining trial population (N = 209).

All but four included trials, [@CD009913-bbs2-0004], [@CD009913-bbs2-0005], [@CD009913-bbs2-0007], and [@CD009913-bbs2-0010], compared FDCs versus single‐drug formulations during the whole treatment. The four remaining trials, [@CD009913-bbs2-0004], [@CD009913-bbs2-0005], [@CD009913-bbs2-0007], and [@CD009913-bbs2-0010], compared FDCs versus single‐drug formulations exclusively during the intensive phase. In [@CD009913-bbs2-0004] and [@CD009913-bbs2-0005] all participants received FDCs during the continuation phase. [@CD009913-bbs2-0007] did not report the continuation phase, and in [@CD009913-bbs2-0010] all participants received single‐drug formulations during the continuation phase. No trial compared FDCs versus single‐drug formulations exclusively during the continuation phase.

In [Table 11](#CD009913-tbl-0011){ref-type="table"}, we describe the doses administered during the intensive phase in all trials for both treatment groups (FDCs and single‐drug formulations). [Table 11](#CD009913-tbl-0011){ref-type="table"} also shows a simulation of doses received by participants during the intensive phase according to body weight.Table 3Comparison of given dose between fixed‐dose combinations and single‐drug formulations during the intensive phase in the included studies**TrialRegimen treatmentDirectly observed therapyDosingDose simulation during intensive phaseComment45 kg participant60 kg participantFixed‐doseSingle‐doseFixed‐doseSingle‐dose**[@CD009913-bbs2-0001]2HRZE/4HRMode of drugs administration: not reportedBy weight categoriesUnclearUnclearUnclearUnclearThe trial authors state: \"The mean daily doses of INH, PZA and EMB administered during the initiation phase in the 4‐FDC group were significantly lower than those administered in the ST group; RMP doses were similar in both groups\".[@CD009913-bbs2-0002]2HRZ/4HRAt the beginning of intensive phaseBy weight categoriesH: 250 mg\
R: 600 mg\
Z: 1500 mgH: 300 mg\
R: 450 mg\
Z: 1500 mgH: 300 mg\
R: 720 mg\
Z: 1800 mgH: 300 mg\
R: 600 mg\
Z: 2000 mgDuring directly observed treatment (DOT), \"health personal\" supervised treatment. Time with DOT is unclear.[@CD009913-bbs2-0003]2HRZ/4HRNoBy weight categories only for FDCsH: 225 mg\
R: 450 mg\
Z: 1200 mgNot reportedH: 300 mg\
R: 600 mg\
Z: 1600 mgNot reportedSelf‐administered treatment was done during the whole treatment. Dose used for single‐drug formulations: not reported.[@CD009913-bbs2-0004]2HRZE/4HR^1^During 6 days a weekBy weight categoriesH: 225 mg\
R: 450 mg\
Z: 1200 mg\
E: 825 mgH: 250 mg\
R: 450 mg\
Z: 1200 mg\
E: 800 mgH: 300 mg\
R: 600 mg\
Z: 1600 mg\
E: 1100 mgH: 300 mg\
R: 600 mg\
Z: 1600 mg\
E: 1200 mgThe trial authors state: \"In the majority of the trial centers, treatment was fully supervised for a minimum of 6 days a week\". Every treatment dose was taken under the supervision of the medical staff.[@CD009913-bbs2-0005]2HRZE/4HRDuring the intensive phaseNot reportedNot reportedNot reportedNot reportedNot reportedThe supervision mechanism during DOT is unclear, and only mention \"strictly supervised\". Self‐administered treatment was done during the continuation phase.[@CD009913-bbs2-0006]2HRZ/4HR^2^NoBy weight categoriesH: 320 mg\
R: 480 mg\
Z: 1000 mgUnclearH: 400 mg\
R: 600 mg\
Z: 1250 mgUnclearSelf‐administered treatment during the whole treatment.[@CD009913-bbs2-0007]4HRZEMode of drugs administration: not reportedBy weight categoriesMairin‐P: 4 tablets +\
H: 225 mgH: 450 mg\
R: 450 mg\
Z: 900 mg\
E: 1125 mgMairin‐P: 5 tablets +\
H: 300 mgH: 600 mg\
R: 600 mg\
Z: 1200 mg\
E: 1500 mgStreptomycin was added in 2 of the 4 randomized groups^3^.[@CD009913-bbs2-0008]2HRZE/4HRENoBy weight categoriesH: 200 mg\
R: 480 mg\
Z: 1000 mg\
E: not reportedH: 300 mg\
R: 450 mg\
Z: 1500 mg\
E: 1200 mgH: 250 mg\
R: 600 mg\
Z: 1250 mg\
E: not reportedH: 300 mg\
R: 600 mg\
Z: 1500 mg\
E: 1200 mgSelf‐administered treatment during the whole treatment.[@CD009913-bbs2-0009]2HRZE/3HROnce a weeklyBy weight categoriesAverage dose\
H: 225 mg\
R: 450 mg\
Z: 1200 mg\
E: 825 mgAverage\
dose\
H: 300 mg\
R: 450 mg\
Z: 1500 mg\
E: 750 mgAverage dose\
H: 225 mg\
R: 450 mg\
Z: 1200 mg\
E: 825 mgAverage dose\
H: 300 mg\
R: 450 mg\
Z: 1500 mg\
E: 750 mgThe study authors state: \"The loose drug regimen contained higher dosages of H and Z and lower dosage for E compared to the FDCs\".\
Drugs \"were given under supervision at health facilities\" during DOT.\
Self‐administered treatment was done the remaining days.[@CD009913-bbs2-0010]Three different regimes were given^4^During the whole treatmentBy weight categoriesH: 250 mg\
R: 600 mg\
Z: 1500 mg\
S: 750 mgH: 300 mg\
R: 600 mg\
Z: 1500 mg\
S: 750 mgH: 300 mg\
R: 720 mg\
Z: 1800 mg\
S: 750 mgH: 300 mg\
R: 600 mg\
Z: 2000 mg\
S: 750 mgThe supervision mechanism during DOT is not clear. And only mention: DOT was given \"at the community health clinic\".[@CD009913-bbs2-0011]2HRZE/4HRETreatment was given as TDO 5 days per week and self‐administered during weekendsBy weight categoriesH: 320 mg\
R: 480 mg\
Z: 1000 mgH: 300 mg\
R: 450 mg\
Z: 1125 mg\
E: 900 mgH: 400 mg\
R: 600 mg\
Z: 1250 mgH: 300 mg\
R: 600 mg\
Z: 1500 mg\
E: 1200 mgDOT was supervised by \"health workers\". The ethambutol dose in FDCs groups was not reported.[@CD009913-bbs2-0012]2HRZE/4HREDuring the intensive phaseBy weight categories^5^H: 300 mg\
R: 480 mg\
Z: 1400 mg\
E: 1000 mgH: 300 mg\
R: 450 mg\
Z: 1500 mg\
E: 1200 mg^5^H: 375 mg\
R: 600 mg\
Z: 1750 mg\
E: 1250 mgH: 400 mg\
R: 600 mg\
Z: 2000 mg\
E: 1600 mgThe supervision mechanism during DOT is unclear and only mention: \"directly observed therapy was followed for each patient on a daily basis\".[@CD009913-bbs2-0013]2HRZ/4HRDuring the\
intensive phaseBy weight categoriesH: 320 mg\
R: 400 mg\
Z: 1000 mgH: 300 mg\
R: 450 mg\
Z: 1500 mgH: 400 mg\
R: 600 mg\
Z: 1250 mgH: 300 mg\
R: 600 mg\
Z: 1500 mgThe trial authors state: \"All drugs were taken under close supervision of a health care provider\".[@CD009913-bbs2-0014]2HRZ/4HROnly for a part of participants^6^By weight categoriesH: 320 mg\
R: 480 mg\
Z: 1000 mgH: 300 mg\
R: 450 mg\
Z: 1500 mgH: 320 mg\
R: 480 mg\
Z: 1000 mgH: 300 mg\
R: 600 mg\
Z: 1500 mgThere were 3 kinds of treatment management combined with 3 supervision models.[^5]

In [@CD009913-bbs2-0001] and [@CD009913-bbs2-0009], there were some differences in doses between the intervention and control groups. In [@CD009913-bbs2-0001], \"the mean daily dosage of H, Z and E in FDCs group was lower than in single‐drug formulations group\". Moreover, FDCs were administered on the basis of body weight according to international recommendations (the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease; [@CD009913-bbs2-0040]), and single‐drug formulations were administered according to the national treatment standards of each included country. In [@CD009913-bbs2-0009], compared with FDCs (given according to WHO recommendations; [@CD009913-bbs2-0054]), single‐formulation regimens contained higher doses of isoniazid and pyrazinamide and lower doses of ethambutol. However, the dose was adjusted to body weight in both groups (intervention and control) (see [Table 11](#CD009913-tbl-0011){ref-type="table"}).

Nine included trials used daily medication during the intensive and continuation phase ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0002]; [@CD009913-bbs2-0003]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0012]; [@CD009913-bbs2-0013]; [@CD009913-bbs2-0014]). Four included trials used daily medication during the intensive phase, and intermittent medication during the continuation phase ([@CD009913-bbs2-0004]; [@CD009913-bbs2-0005]; [@CD009913-bbs2-0009]; [@CD009913-bbs2-0010]). One trial ([@CD009913-bbs2-0007]) reported daily medication for the intervention groups and did not report the frequency of treatment in control groups. None of the clinical trials used treatment twice a week.

Seven trials used directly observed treatment (DOT); five during the whole treatment ([@CD009913-bbs2-0004]; [@CD009913-bbs2-0005]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0013]) and two only during the intensive phase ([@CD009913-bbs2-0002]; [@CD009913-bbs2-0012]). In [@CD009913-bbs2-0002] and [@CD009913-bbs2-0012], treatment was self‐administered during the continuation phase. Four trials used self‐administered treatment during the whole therapy ([@CD009913-bbs2-0003]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0009]). Two trials did not report the mode of treatment administration ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0007]). In [@CD009913-bbs2-0014], there were three kinds of treatment management combined with three supervision models, respectively.

During the intensive phase, five trials used four drugs in FDC ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0007]; [@CD009913-bbs2-0009]; [@CD009913-bbs2-0012]), eight trials used three drugs in FDC ([@CD009913-bbs2-0002]; [@CD009913-bbs2-0003]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0013]; [@CD009913-bbs2-0014]), and one trial used two drugs in FDC and two additional single drugs ([@CD009913-bbs2-0005]). We have detailed each FDC used by each included trial in the \'[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\' section.

[@CD009913-bbs2-0007] compared daily treatment with four FDCs versus four single‐drug formulations during the intensive phase. It is unclear whether treatment was supervised or self‐administered, and when follow‐up concluded. The trial gave data precisely up to the end of the intensive phase (four months after initiation of treatment).

#### Outcomes {#CD009913-sec4-0009}

We have described below the outcomes for the 13 trials we included in the quantitative analyses.

##### A combined endpoint of treatment failure, relapse, or death {#CD009913-sec5-0001}

No included trials examined the combined outcome.

##### Treatment failure {#CD009913-sec5-0002}

Seven included trials assessed this outcome ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0002]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0009]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0011]). All but one trial, [@CD009913-bbs2-0004], reported treatment failure based only on bacteriological confirmation in all participants. [@CD009913-bbs2-0004] also reported failure based on "clinical or radiographic deterioration in absence of bacteriological confirmation" in only one participant. See [Table 9](#CD009913-tbl-0009){ref-type="table"} for each included trials\' suggested definition of treatment failure.

##### Relapse {#CD009913-sec5-0003}

This outcome was available in nine included trials ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0002]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0009]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0012]; [@CD009913-bbs2-0013]). All but two included trials, [@CD009913-bbs2-0006] and [@CD009913-bbs2-0009], reported relapse based only on bacteriological confirmation in all participants. These two RCTs reported relapse confirmed by bacteriological results but also based on other methods, such as information from interviews and verbal autopsies in 19 participants ([@CD009913-bbs2-0009]), or X‐ray in one participant ([@CD009913-bbs2-0006]). See [Table 9](#CD009913-tbl-0009){ref-type="table"} for each included trials\' definition of relapse.

##### Death {#CD009913-sec5-0004}

Eleven trials assessed this outcome ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0003]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0009]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0012]; [@CD009913-bbs2-0013]; [@CD009913-bbs2-0014]). We included all causes of death.

The included trials were published between 1987 and 2015, which made it impossible to present the same definitions of treatment failure and relapse across all trials. For these two outcomes, we used the trial authors\' proposed definitions and collected data based on bacteriological confirmation (sputum smear or culture results) (see [Table 9](#CD009913-tbl-0009){ref-type="table"}).

##### Sputum smear or culture conversion {#CD009913-sec5-0005}

For this outcome, all included trials reported data at two months and only seven trials reported data at six months ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0009]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0013]; [@CD009913-bbs2-0014]).

##### Time to sputum smear or culture conversion {#CD009913-sec5-0006}

Only [@CD009913-bbs2-0012] reported on this outcome.

##### Time to relapse {#CD009913-sec5-0007}

Only [@CD009913-bbs2-0010] reported on this outcome.

##### Treatment adherence {#CD009913-sec5-0008}

Five included trials reported on this outcome ([@CD009913-bbs2-0002]; [@CD009913-bbs2-0003]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0014]) at the end of treatment (EOT) and three trials also reported on it during the first eight weeks of treatment ([@CD009913-bbs2-0002]; [@CD009913-bbs2-0003]; [@CD009913-bbs2-0006]). Each trials used different adherence assessment methods.

[@CD009913-bbs2-0002] determined adherence by testing urine for isoniazid metabolites and considered participants with at least one negative urine test as non‐adherent.[@CD009913-bbs2-0003] assessed appointment‐keeping behaviour, by asking participants about missed doses, by pill counts, and by testing urine for isoniazid metabolites. [@CD009913-bbs2-0003] considered participants who missed more than 14 days of any study drug without medical advice, or participants that had four consecutively missed appointments as non‐adherent.[@CD009913-bbs2-0006] determined adherence by delay in drug collection and surprise pill count (surprise visit once a month). The delay was measured in drug‐days, expressed as a percentage of total treatment days and classified as either: none, 1% to 10% and greater than 10%. For this Cochrane review, we considered participants with no drug‐days lost as adherent.[@CD009913-bbs2-0008] determined adherence by "cases lost to follow‐up and cases changed to another regimen during treatment\".In [@CD009913-bbs2-0014], the supervision process was unclear (by testing urine or by indirect methods).

See [Table 9](#CD009913-tbl-0009){ref-type="table"} for details on treatment adherence in each trial.

##### Acquisition of drug resistance {#CD009913-sec5-0009}

Three trials reported on this outcome ([@CD009913-bbs2-0002]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0010]). See [Table 9](#CD009913-tbl-0009){ref-type="table"} for details on acquisition of drug resistance in each trial.

##### Patient satisfaction {#CD009913-sec5-0010}

###### General satisfaction {#CD009913-sec6-0001}

Only [@CD009913-bbs2-0002] reported on this outcome, and assessed it by semi‐directed interviews with targeted questions posed by non‐medical staff at the end of the eighth week of treatment.

###### Problems swallowing, convenient number of tablets, and acceptable taste {#CD009913-sec6-0002}

Only [@CD009913-bbs2-0001] reported on this outcome, and noted it at two months.

##### Adverse events {#CD009913-sec5-0011}

###### Serious (death, hospitalizations) {#CD009913-sec6-0003}

Six trials reported serious adverse events ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0005]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0012]).

###### Adverse events leading to discontinuation of therapy {#CD009913-sec6-0004}

All trials reported this outcome.

###### Other adverse events {#CD009913-sec6-0005}

All included trials but four, [@CD009913-bbs2-0006], [@CD009913-bbs2-0008], [@CD009913-bbs2-0009], and [@CD009913-bbs2-0011], reported other adverse events. The most frequent adverse events in this category were gastrointestinal and skin disorders ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0002]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0012]). Other adverse events mentioned were joint and nerve disorders ([@CD009913-bbs2-0002]); rheumatic and hepatic disorders ([@CD009913-bbs2-0004]); vestibular reactions ([@CD009913-bbs2-0010]); and jaundice, numbness, and joint pain ([@CD009913-bbs2-0012]). In [@CD009913-bbs2-0014], the other most frequent adverse event was liver damage combined with either jaundice or gastrointestinal disorders. [@CD009913-bbs2-0003] and [@CD009913-bbs2-0013] gave no details of the type of other adverse events reported. In [@CD009913-bbs2-0005], no participant experienced further adverse events.

##### Outcomes not reported in this Cochrane review {#CD009913-sec5-0012}

See the \'[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\' section for the outcomes assessed in each clinical trial that we did not report in this Cochrane review.

### Excluded studies {#CD009913-sec3-0020}

We have stated the reasons for exclusion of studies in the \'[Characteristics of excluded studies](#CD009913-sec2-0020){ref-type="sec"}\' section.

Risk of bias in included studies {#CD009913-sec2-0009}
--------------------------------

We rated only one trial as free from risk of bias in all assessed domains ([@CD009913-bbs2-0001]), and another one as at low risk of bias ([@CD009913-bbs2-0004]). Overall, we rated the risk of bias as suboptimal in the remaining included trials. We have listed the \'Risk of bias\' details for all included trials in the \'Risk of bias\' tables in the \'[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\' section. For a summary of the \'Risk of bias\' assessments see [Figure 3](#CD009913-fig-0003){ref-type="fig"} and [Figure 4](#CD009913-fig-0004){ref-type="fig"}.Figure 3\'Risk of bias\' summary: review authors\' judgements about each \'Risk of bias\' item for each included trial.Figure 4\'Risk of bias\' graph: review authors\' judgements about each \'Risk of bias\' item presented as percentages across all included trials.

### Allocation {#CD009913-sec3-0021}

We judged only two trials as free from selection bias ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0004]). We considered four trials at low risk of bias for random sequence generation, but not for allocation concealment ([@CD009913-bbs2-0007]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0012]; [@CD009913-bbs2-0013])

[@CD009913-bbs2-0009] was at high risk of bias for both random sequence generation and allocation concealment, because it performed randomization by the judgment of the clinician through alternate allocation of eligible participants to each regimen to obtain equal numbers for both groups.

The remaining trials were at unclear risk of bias for selection bias.

### Blinding {#CD009913-sec3-0022}

We considered all trials to be free of performance and detection bias. Four trials were described as open trials ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0003]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0011]), and blinding was not stated in the remaining trials.

For open trials and for those that did not describe the blinding methods, we concluded that outcomes were unlikely to be influenced by the lack of blinding because most outcomes were objective and measurable.

### Incomplete outcome data {#CD009913-sec3-0023}

We considered seven trials to be at low risk of bias ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0005]; [@CD009913-bbs2-0008]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0012]; [@CD009913-bbs2-0013]). In [@CD009913-bbs2-0001], [@CD009913-bbs2-0004], [@CD009913-bbs2-0008], and [@CD009913-bbs2-0010], the missing outcome data were balanced in numbers across intervention groups and the reasons for missing data were similar. In [@CD009913-bbs2-0005], the trial authors used appropriate methods for imputing missing data. In [@CD009913-bbs2-0012], there were no missing outcome data. There were few missing data in [@CD009913-bbs2-0013] and reasons for loss were given.

We judged six trials at high risk of bias ([@CD009913-bbs2-0002]; [@CD009913-bbs2-0003]; [@CD009913-bbs2-0007]; [@CD009913-bbs2-0009]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0014]).

Some of these trials did not fully report the reasons for participants\' withdrawal or were likely to be related to lack of efficacy, or adverse events, or the number of withdrawals was unbalanced between the intervention and control group.

We considered [@CD009913-bbs2-0006] as unclear regarding attrition bias.

### Selective reporting {#CD009913-sec3-0024}

We judged two trials to be free from risk of reporting bias because the published reports included most of the expected outcomes ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0008]).

We rated three trials at high risk of bias ([@CD009913-bbs2-0004]; [@CD009913-bbs2-0007]; [@CD009913-bbs2-0009]). In [@CD009913-bbs2-0004], most of the primary and secondary outcomes differed from those stated in the available protocol. In [@CD009913-bbs2-0007] and [@CD009913-bbs2-0009], the published reports failed to include key results expected to be reported in clinical trials in this field.

We considered selective reporting to be unclear in nine trials ([@CD009913-bbs2-0002]; [@CD009913-bbs2-0003]; [@CD009913-bbs2-0005]; [@CD009913-bbs2-0006]; [@CD009913-bbs2-0010]; [@CD009913-bbs2-0011]; [@CD009913-bbs2-0012]; [@CD009913-bbs2-0013]; [@CD009913-bbs2-0014]).

### Other potential sources of bias {#CD009913-sec3-0025}

We judged all but two included trials free from other potential sources of bias ([@CD009913-bbs2-0003]; [@CD009913-bbs2-0007]).

We rated [@CD009913-bbs2-0003] at high risk of bias because this trial was designed with an amended protocol of a former study, and followed an unbalanced randomization scheme. We considered [@CD009913-bbs2-0007] to be at unclear risk as it provided insufficient information to enable us to assess whether an important risk of bias existed.

Effects of interventions {#CD009913-sec2-0010}
------------------------

See: [Table 1](#CD009913-tbl-0001){ref-type="table"}

See \'Summary of findings\' table 1 and \'Summary of findings\' table 2 ([Table 1](#CD009913-tbl-0001){ref-type="table"}; [Table 12](#CD009913-tbl-0012){ref-type="table"} ).Table 4\'Summary of findings\' table 2Fixed‐dose combinations (FDCs) compared to single‐drug formulations for treating newly diagnosed pulmonary tuberculosis (TB)**Participant or population:** treating pulmonary TB **Setting:** hospitals and health centres for TB treatment **Intervention:** fixed‐dose combinations **Comparison:** single‐drug formulations as available data: sensitivity analysis considering the global risk of bias**OutcomesIllustrative comparative risks^\*^ (95% CI)Relative effect (95% CI)Number of participants (trials)Quality of the evidence (GRADE)Assumed risk**\
**single‐drug formulationsCorresponding risk**\
**FDCs**Combined endpoint of treatment failure, relapse, or death\*\*---------(0 RCTs)---Treatment failure22 per 100025 per 1000 (15 to 42)RR 1.17 (0.70 to 1.93)2507 (2 RCTs)⊕⊕⊕⊝ moderate^1,2,3,4^Relapse79 per 100088 per 1000 (68 to 115)RR 1.12 (0.86 to 1.46)2293 (2 RCTs)⊕⊕⊕⊝ moderate^1,2,3,4^Death9 per 100012 per 1000 (6 to 26)RR 1.35 (0.63 to 2.93)2470 (2 RCTs)⊕⊕⊕⊝ moderate^2,4,5,6^Sputum smear or culture conversion at end of treatment827 per 1000802 per 1000 (761 to 851)RR 0.97 (0.92 to 1.03)1159 (1 RCT)⊕⊕⊕⊕ high^2,4,7,8^Serious adverse events17 per 100025 per 1000 (15 to 42)RR 1.44 (0.86 to 2.44)2703 (2 RCTs)⊕⊕⊕⊝ moderate^1,2,3,4^Adverse events leading to discontinuation of therapy18 per 100030 per 1000 (19 to 50)RR 1.71 (1.04 to 2.81)2703 (2 RCTs)⊕⊕⊕⊝ moderate^1,2,3,4^\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). \*\*Outcome not reported. **Abbreviations:** CI: confidence interval; RR: risk ratio; TB: tuberculosis; FDCs: fixed‐dose combinations; RCTs: randomized controlled trial.**GRADE Working Group grades of evidence** **High quality:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate quality:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low quality:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. **Very low quality:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.[^6]

We included 13 RCTs in quantitative analyses, which included 5824 randomized participants. All trials compared FDCs versus single‐drug formulations for the treatment of pulmonary TB in newly diagnosed participants.

The trials and the meta‐analyses were underpowered to allow us to confidently detect or exclude clinically important changes on the primary dichotomous outcomes related to treatment efficacy (treatment failure and relapse), the sputum smear or culture conversion at EOT, death, and adverse events (see [Table 13](#CD009913-tbl-0013){ref-type="table"}).Table 5Optimal information size calculations: fixed‐dose combinations versus single‐drug formulations (Comparison 1)**OutcomesAssumed riskClinically important reductionOptimal sample size ^1,2^Single‐drug formulationsAbsoluteRelativeTreatment failure**2.2 %0.5%25%6092**Relapse**2.3 %0.5%25%4718**Death**^3^0.9 %0.1%4.5%737,340**Sputum/culture conversion at end of treatment**88.7%0.5%0.6%95,044**Serious adverse events**1.5 %0.1%6.7%12,356**Adverse events leading to discontinuation of therapy**4.1 %0.5%24.4%325,024[^7]

### A combined endpoint of treatment failure, relapse, or death {#CD009913-sec3-0026}

We did not identify any trials that examined the combined outcome.

### Treatment failure {#CD009913-sec3-0027}

The proportion of participants that experienced treatment failure was similar with FDCs and single‐drug formulations (3606 participants, seven trials, [Analysis 1.1](#CD009913-fig-00101){ref-type="fig"}).

### Relapse {#CD009913-sec3-0028}

Overall, there is a trend towards a higher number of relapses with the use of FDCs although the confidence interval (CI) included no difference (RR 1.28, 95% CI 1.00 to 1.64; I² statistic = 0; 3621 participants, 10 trials, [Analysis 1.2](#CD009913-fig-00102){ref-type="fig"}). In the analysis of trials at high or unclear risk of bias, we found a statistically significant increase in relapse with FDCs (RR 2.84, 95% CI 1.34 to 6.00; I² statistic = 0; 1328 participants, eight trials, [Analysis 2.2](#CD009913-fig-00202){ref-type="fig"}). Inclusion of only the trials at low risk of bias showed no difference between FDCs or single‐drug formulations (2293 participants, two trials, [Analysis 2.2](#CD009913-fig-00202){ref-type="fig"}).

### Death {#CD009913-sec3-0029}

There was no significant difference between the two groups for all causes of death (4800 participants, 11 trials, [Analysis 1.3](#CD009913-fig-00103){ref-type="fig"}).

### Sputum smear or culture conversion {#CD009913-sec3-0030}

Data were available to assess sputum smear or culture conversion at two and six months. There was no significant difference between treatment with FDCs or single‐drug formulations in sputum smear or culture conversion either at two months (4836 participants, 13 trials, [Analysis 1.4](#CD009913-fig-00104){ref-type="fig"}), or at six months (2319 participants, seven trials, [Analysis 1.5](#CD009913-fig-00105){ref-type="fig"}).

### Time to sputum smear or culture conversion {#CD009913-sec3-0031}

Only one trial reported data for this outcome ([@CD009913-bbs2-0012]), but data were insufficient to estimate hazard ratios (HRs) and we could not assess any treatment effect. The mean number of days for sputum conversion was 34.85 days (standard deviation (SD) 17.39) for FDCs with 194 participants, and 37.97 days (SD 18.35) for single‐drug formulations with 99 participants.

### Time to relapse {#CD009913-sec3-0032}

Only one trial reported data for this outcome ([@CD009913-bbs2-0010]), but data were insufficient to estimate HRs, and we could not assess any treatment effect. The mean number of months to relapse was 15 months (SD 16.722) for FDCs with 12 participants, and 18 months (SD 20.232) for single‐drug formulations with three participants.

### Treatment adherence {#CD009913-sec3-0033}

Data were available to evaluate treatment adherence at eight weeks and at the EOT. There was no significant difference in treatment adherence between the two interventions either at eight weeks (881 participants, three trials, [Analysis 1.6](#CD009913-fig-00106){ref-type="fig"}) or at the EOT (1229 participants, five trials, [Analysis 1.7](#CD009913-fig-00107){ref-type="fig"}).

### Acquisition of drug resistance {#CD009913-sec3-0034}

There was no significant difference in the probability of acquiring drug resistance (491 participants, three trials, [Analysis 1.8](#CD009913-fig-00108){ref-type="fig"}).

### Patient satisfaction {#CD009913-sec3-0035}

#### General satisfaction {#CD009913-sec4-0010}

One trial, [@CD009913-bbs2-0002], recorded general satisfaction and did not show any differences (222 participants, [Analysis 1.9](#CD009913-fig-00109){ref-type="fig"}).

#### Problems swallowing {#CD009913-sec4-0011}

One trial, [@CD009913-bbs2-0001], reported problems swallowing and there was no significant difference between treatments (1023 participants, [Analysis 1.9](#CD009913-fig-00109){ref-type="fig"}).

#### Convenient number of tablets {#CD009913-sec4-0012}

Only [@CD009913-bbs2-0001] reported this outcome. Participants treated with FDCs found the number of tablets more convenient compared with participants treated with single‐drug formulations (RR 1.50, 95% CI 1.37 to 1.64; 1045 participants, one trial, [Analysis 1.9](#CD009913-fig-00109){ref-type="fig"}).

#### Acceptable taste {#CD009913-sec4-0013}

[@CD009913-bbs2-0001] reported on this outcome. Participants treated with FDCs recognized that the tablets tasted better compared to participants who were treated with single‐drug formulations (RR 1.39, 95% CI 1.27 to 1.51; 1044 participants, one trial, [Analysis 1.9](#CD009913-fig-00109){ref-type="fig"}).

### Adverse events {#CD009913-sec3-0036}

#### Serious adverse events (death, hospitalizations) {#CD009913-sec4-0014}

There was no statistically significant difference in the number of serious adverse events in the meta‐analysis of the six trials that reported this outcome (3388 participants, six trials, [Analysis 1.10](#CD009913-fig-00110){ref-type="fig"}).

#### Adverse events leading to discontinuation of therapy {#CD009913-sec4-0015}

There was no difference between the treatment groups regarding the adverse events that led to discontinuation of treatment (5530 participants, 13 trials, [Analysis 1.11](#CD009913-fig-00111){ref-type="fig"}).

#### Other adverse events {#CD009913-sec4-0016}

There was a trend of fewer other adverse events with treatment with FDCs, which just reaches standard levels of statistical significance (RR 0.85, 95% CI 0.72 to 1.00; I² statistic = 38%; 4639 participants, nine trials, [Analysis 1.12](#CD009913-fig-00112){ref-type="fig"}).

### Subgroup analysis {#CD009913-sec3-0037}

We were able to perform four subgroup analyses based on the available data.

FDCs administered only during the intensive phase versus FDCs administered for the whole treatment.Daily regimen for the whole treatment versus daily regimen during in the intensive phase followed by intermittent regimen in the continuation phase.Supervised treatment versus self‐administered treatment during the intensive phase.Trials with four drugs as FDCs versus trials with three or two drugs as FDCs during the intensive phase.

There were subgroup differences on relapse in three subgroup analyses.

FDCs administered only in the intensive phase versus FDCs for the whole treatment: relapses were more frequent in participants treated with FDCs when combined tablets were administered only in the intensive phase (RR 3.94, 95% CI 1.13 to 13.78; 251 participants, one trial, [Analysis 4.2](#CD009913-fig-00402){ref-type="fig"}).Daily medication for the whole treatment versus daily medication in the intensive phase followed by intermittent treatment in the continuation phase: relapses were more frequent in participants treated daily with FDCs during the intensive phase and intermittently during the continuation phase (RR 1.72, 95% CI 1.07 to 2.75; 1771 participants, three trials, [Analysis 5.2](#CD009913-fig-00502){ref-type="fig"}).Four drugs as FDCs versus trials with three or two drugs as FDCs in the intensive phase: relapses were more frequent with FDCs in participants treated with three or two drugs as FDCs in the intensive phase (RR 2.55, 95% CI 1.07 to 6.06; 848 participants, five trials, [Analysis 7.2](#CD009913-fig-00702){ref-type="fig"}).

These differences are due almost exclusively to one trial, [@CD009913-bbs2-0010], which used a FDCs with three active oral ingredients (H, R and Z) in the intensive phase for the intervention group and single‐drug formulations for all participants in the continuation phase. In addition, there was a daily treatment during the intensive phase which was followed by intermittent treatment in the continuation phase. This trial had a higher number of relapses in the intervention arm, possibly due to the change from FDCs given daily during the intensive phase to single‐drug formulations given three times a week during the continuation phase.

Overall, we did not observe any statistically significant subgroup differences in the remaining outcomes for the rest of the performed analyses.

There were no available data for subgroup analyses of HIV‐positive versus HIV‐negative participants or for clinically diagnosed versus laboratory diagnosed participants. Only two trials reported the HIV status of participants and neither of them stratified their results according to this status ([@CD009913-bbs2-0001]; [@CD009913-bbs2-0004]). All included trials reported pulmonary TB diagnosed by bacteriological results, and in no case by clinical diagnosis.

### Sensitivity analysis {#CD009913-sec3-0038}

#### Risk of bias {#CD009913-sec4-0017}

We performed a sensitivity analysis by risk of bias of included trials. We pooled results from [@CD009913-bbs2-0001] and [@CD009913-bbs2-0004], the two trials at low risk of selection bias.

Relapse: the analysis restricted to the trials at low risk of bias showed no difference between treatment with FDCs or single‐drug formulations (2293 participants, two trials, [Analysis 2.2](#CD009913-fig-00202){ref-type="fig"}).

Adverse events leading to discontinuation of therapy: the risk of experiencing this outcome was higher among those who received FDCs than among those who received single‐drug formulations in the analysis of trials at low risk of selection bias (RR 1.71, 95% CI 1.04 to 2.81; I² statistic = 0%; 2703 participants, two trials, [Analysis 2.8](#CD009913-fig-00208){ref-type="fig"}).

For the remaining outcomes, the analyses reached similar results to those of the main comparison (see [Data and analyses](#CD009913-sec1-0011){ref-type="sec"}: Comparison 2 \'Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias\'.

#### ITT analysis {#CD009913-sec4-0018}

We also performed a sensitivity analysis under an ITT analysis. We performed this analysis for the following outcomes: a) failure; b) relapse; and c) sputum smear or culture conversion (at two months of starting treatment and at EOT). There was no significant difference in relapse between the two interventions (4716 participants, 10 trials, [Analysis 3.2](#CD009913-fig-00302){ref-type="fig"}). For the rest of the outcomes, this analysis showed similar results to those of the main analysis (see [Data and analyses](#CD009913-sec1-0011){ref-type="sec"}: Comparison 3 \'Fixed‐dose combinations versus single‐drug formulations: sensitivity analysis by intention‐to‐treat\').

#### Assessment of reporting biases {#CD009913-sec4-0019}

The funnel plot for sputum smear or culture conversion at two months in the comparison of treatment with FDCs versus single‐drug formulations showed no inherent risk of publication bias in the trials included in the meta‐analyses, although these analyses included few trials ([Figure 5](#CD009913-fig-0005){ref-type="fig"}). The funnel plot for death showed a similar result (figure not shown).Figure 5Funnel plot of comparison: 1 Fixed‐dose combinations versus single‐drug formulations as available data, outcome: 1.4 Sputum smear or culture conversion at two months of starting treatment.

Discussion {#CD009913-sec1-0006}
==========

Summary of main results {#CD009913-sec2-0011}
-----------------------

This Cochrane review included 13 RCTs with a total of 5824 participants, and overall did not find any difference between fixed‐dose combinations (FDCs) and single‐drug formulations for the treatment of pulmonary tuberculosis (TB) in newly diagnosed people. We have presented a summary of the evidence in \'Summary of findings\' table 1 ([Table 1](#CD009913-tbl-0001){ref-type="table"}) (there is an additional \'Summary of findings\' table using data from the sensitivity analysis in the Additional tables section, [Table 12](#CD009913-tbl-0012){ref-type="table"}).

We did not detect any difference in treatment failure and death between people treated with FDCs or single‐drug formulations (*moderate quality evidence*). Relapse may slightly more frequent in people treated with FDCs compared to single‐drug formulations (*low quality evidence*).

FDCs and single‐drug formulations have similar effects on sputum smear or culture conversion at the end of treatment (EOT) (*high quality evidence*) and on serious adverse events (*moderate quality evidence*). There were no differences in adverse events leading to discontinuation of therapy (*low quality evidence*) between people treated with FDCs or single‐drug formulations.

The analyses for these outcomes were underpowered to detect clinically important differences ([Table 13](#CD009913-tbl-0013){ref-type="table"}).

Overall completeness and applicability of evidence {#CD009913-sec2-0012}
--------------------------------------------------

All included trials except [@CD009913-bbs2-0003] were conducted in high TB‐burden countries and low‐ and middle‐income countries. All included trials compared the use of FDCs with single‐drug formulations in adults, and administered a standard first‐line treatment regimen for people newly diagnosed with pulmonary TB ([Table 10](#CD009913-tbl-0010){ref-type="table"}). Overall, the doses of anti‐TB drugs used were equivalent to the currently recommended doses for pulmonary TB patients ([@CD009913-bbs2-0056]). Although not all the included trials used uniform definitions of outcomes and comparable follow‐up time, we consider these review findings to be widely applicable.

In TB treatment, the dose administered of each drug is crucial. Ideally in clinical trials, FDCs and single‐drug formulations should be compared using equal doses to assess the real effect of the administered dose. Although the included trials administered similar doses in both treatment arms, doses generally were unequal. Only [@CD009913-bbs2-0004] gave equal doses to both treatment arms. Imbalances between treatment arms were more pronounced in some trials with higher doses of some drugs in the single‐drug formulations arm: higher doses of isoniazid and pyrazinamide ([@CD009913-bbs2-0008]; [@CD009913-bbs2-0009]); higher doses of pyrazinamide and ethambutol ([@CD009913-bbs2-0012]); and higher doses of pyrazinamide ([@CD009913-bbs2-0013]; [@CD009913-bbs2-0014]) (see [Table 11](#CD009913-tbl-0011){ref-type="table"}). This may explain the favourable results with single‐drug formulations in some included trials.

There is a lack of data regarding some important outcomes such as acceptability (outcome concerning patients) and acquisition of drug resistance (clinically and bacteriologically relevant outcomes). We analysed general satisfaction, which only [@CD009913-bbs2-0002] recorded, and no problems swallowing and acceptable taste, which [@CD009913-bbs2-0001] recorded. There rest of the included trials had limited data about acceptability. Only three trials reported acquisition of drug resistance ([@CD009913-bbs2-0002]; [@CD009913-bbs2-0004]; [@CD009913-bbs2-0010]; see the \'[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\' section).

TB therapy in real clinical practice may differ from the procedures in clinical trials. Firstly, clinical trials implement interventions that are more similar to directly observed treatments (DOT) than to self‐administered treatments. In clinical practice, self‐administered treatments are more frequent and also, with this mode of administration, participants may interrupt the treatment or take fewer pills than those needed or prescribed, which can lead to drug resistance of the bacteria. In this case, feasibility of administration (potentially better for single‐drug formulations in terms of smaller pills, but better for FDCs in terms of fewer pills to take) and ensuring dosing of all drugs together (better for FDC pills) would be important issues to prevent treatment discontinuation and acquisition of resistance. Additionally, participants included in clinical trials are selected, whereas those participating in clinical practice are not. This means that participants with TB in clinical practice often present with co‐morbid conditions, such as human immunodeficiency virus (HIV) and other diseases that could increase the number of tablets taken daily, which may be a key factor in treatment withdrawal/defaulting. The included trials reported a low percentage of HIV participants, which possibly makes the results less applicable to this population.

The applicability of the evidence from this Cochrane review to a specific country depends on the strength of its healthcare system. Issues in TB treatment in developed countries or urban settings differ from those in resource‐limited countries or rural settings. Factors such as ease of administration, need for directly observed treatment (DOT), and costs of therapy differ in importance depending on the country or setting. Even the implementation of the intervention will differ between settings; for example, methods for DOT may include weekly drug delivery with treatment intake under the supervision of relatives, or daily drug delivery with treatment intake under supervision of a medical staff member. Moreover, differences can occur depending on the way drugs are dispensed to participants: by giving participants appointments at the clinic or hospital, visiting them at home, or applying mixed approaches.

Achievement of high TB cure rates is the most important goal of intervention in TB control. This systematic review provides moderate quality evidence that FDCs present similar efficacy to separate formulations. Nevertheless, FDCs have important features that should be expected to greatly influence the improvement of TB outcomes in the medium and long term and, of course, its control. The recommendation for use of FDCs should also be supported by the characteristics of FDCs. FDCs contain similar doses of individual drugs which can lead to non‐inferior efficacy and similar safety. With FDCs the number of daily tablets can be reduced, and drug management and storage by the patient should be easy; thus making it possible to increase patient satisfaction and decrease medication errors, burden, and cost for patients. Treatment simplifications can reduce the risk of monotherapy and improve treatment compliance. FDC use could improve sputum and culture conversion rate and lower the failure rate, relapse rate, treatment resistance, and morbidity and mortality rates ([Figure 1](#CD009913-fig-0001){ref-type="fig"}).

Two advantages of FDCs are feasibility and ease of administration, which favour treatment compliance and increase patients' quality of life, especially the quality of life of patients that may need additional therapy for concomitant diseases such as HIV. However, single‐drug formulations allow a better dose adjustment to the body weight and avoid the issue of complete interruption of therapy when drug‐specific adverse effects occur ([Figure 1](#CD009913-fig-0001){ref-type="fig"}).

Quality of the evidence {#CD009913-sec2-0013}
-----------------------

We assessed the quality of the evidence using the GRADE approach and presented the results in \'Summary of findings\' table 1 ([Table 1](#CD009913-tbl-0001){ref-type="table"}) and \'Summary of findings\' table 2 ([Table 12](#CD009913-tbl-0012){ref-type="table"}).

The quality of evidence for the efficacy and safety of FDCs is high to low, depending on reported outcomes, due to two main concerns.

Imprecision of results: the quality of the evidence was moderate for treatment failure, death, and serious adverse events, and low for relapse and adverse events leading to discontinuation of therapy. We downgraded the quality of the evidence for these outcomes because the meta‐analysis remained significantly underpowered to confidently prove or exclude clinically important effects.Risk of bias of included studies: the quality of the evidence was low for relapse and adverse events leading to discontinuation of therapy. We downgraded these two outcomes for the difference in results of pooled estimate of effect when we excluded trials at high risk of bias.

The quality of evidence was high for sputum smear or culture conversion at the EOT, which we did not downgrade because the analysis with trials at low risk of bias did not change the effect estimate and the difference in drug doses probably does not affect the comparability of intervention and control group. In addition, there was no statistical heterogeneity among trials that reported this outcome. Moreover, although the optimal information size was not reached (considering an absolute non‐inferiority margin of greater than 0.5% as clinically meaningful), the total sample size and number of events for this outcomes are very large.

Potential biases in the review process {#CD009913-sec2-0014}
--------------------------------------

We minimized the biases in the review process by performance of an exhaustive search strategy, which included the most important bibliographic databases of clinical trials, without time or language limitations. The Information Specialist of the Cochrane Infectious Diseases Group, Vittoria Lutje, performed the search and we checked the reference lists of relevant studies, which decreased the probability that we missed important studies. We were able to obtain all the published papers of the trials and all available data.

Two review authors independently performed study selection and \'Risk of bias\' assessments of included trials. We consulted a third review author to resolve any disagreements. Two review authors independently performed data extraction. We excluded one RCT that met the inclusion criteria from the quantitative analysis because disaggregate results were unavailable.

The assessment of reporting biases did not show a small study effect.

Although we tried to minimize all forms of potential biases in this Cochrane review, we cannot completely exclude the possibility of bias.

Agreements and disagreements with other studies or reviews {#CD009913-sec2-0015}
----------------------------------------------------------

We found two other systematic reviews that compared the use of FDCs and single‐drug formulations in the treatment of pulmonary TB ([@CD009913-bbs2-0038]; [@CD009913-bbs2-0061]).

[@CD009913-bbs2-0038] included 15 RCTs, and coincided with this Cochrane review regarding 10 trials. [@CD009913-bbs2-0061] included 22 studies, and coincided only regarding six trials.

This Cochrane review, [@CD009913-bbs2-0038], and [@CD009913-bbs2-0061] present almost the same results for relapse. [@CD009913-bbs2-0038] found a trend towards higher risk for "treatment failure or disease relapse" (as a combined outcome) with the use of FDCs (risk ratio (RR) 1.28, 95% confidence interval (CI), 0.99 to 1.7). [@CD009913-bbs2-0061] found a trend towards higher risk of relapse (as a single outcome) with the use of FDCs (RR 1.72, 95% CI, 0.98 to 3.02). We also found a similar result of relapse (also as a single outcome) with FDCs (RR 1.28, 95% CI 1.00 to 1.64; [Analysis 1.2](#CD009913-fig-00102){ref-type="fig"}). None of these cases reached statistical significance.

For the remaining coinciding outcomes (acquisition of drug resistance, sputum conversion at two months, overall adverse events, and treatment adherence) neither this Cochrane review nor [@CD009913-bbs2-0038] found any difference between treatment with FDCs or single‐drug formulations.

Overall, in [@CD009913-bbs2-0061] there were no differences between FDCs and single‐drug formulations in the reported outcomes: sputum smear rate (at two months and at the EOT) and adverse events.

Despite the similar results obtained, this Cochrane review presents some methodological differences compared with [@CD009913-bbs2-0038] and [@CD009913-bbs2-0061].

Included studies: we had different inclusion criteria in this Cochrane review. [@CD009913-bbs2-0038] included randomized clinical trials and cohort studies (the latter should include 50 subjects or over) with participants diagnosed with active TB (new patients and patients already treated) with bacteriological confirmation (and treated with FDCs or single‐drug formulations). [@CD009913-bbs2-0061] included RCTs and controlled clinical trials that compared anti‐TB treatment given as FDCs with non‐FDC regimens (single drugs or plate‐type‐combined drugs) in the initial treatment of smear‐positive pulmonary TB. Neither [@CD009913-bbs2-0038] nor [@CD009913-bbs2-0061] accounted for the comparability of treatment regimens between intervention and control groups (same regimens in both groups). We included only RCTs that compared FDCs and single‐drug formulations with the same drugs in both treatment arms for new participants with pulmonary TB.Treatment failure and relapse, types of outcomes measured: [@CD009913-bbs2-0038] presented treatment failure and relapse as a combined outcome. It is known that treatment failure and relapse are not the same thing; consequently, two different variables were analysed jointly. Also, the trial authors provided definitions of these two variables, which already differ from each other, that differed widely. [@CD009913-bbs2-0061] presented the relapse rate as a single outcome. Treatment failure was not reported. We presented both outcomes (treatment failure and relapse) as single outcomes.Data synthesis: [@CD009913-bbs2-0038] calculated a pooled estimate of treatment using a fixed‐effect model and [@CD009913-bbs2-0061] used a fixed‐effect model when P was greater than 0.05 with the Q‐test, or a random‐effects model otherwise. We calculated a pooled estimate of treatment using a fixed‐effect model when minimal heterogeneity was present (I² statistic value of less than 50%) and a random‐effects model when moderate heterogeneity was present (I² statistic value of greater than 50%). We did not perform a meta‐analysis with a substantial I² statistic value (greater than 75%).Linking overall quality of the evidence with the effect estimates: [@CD009913-bbs2-0038] adopted the PRISMA statement for the methods and results sections, but did not summarize the main findings, including the strength of evidence, for each main outcome. [@CD009913-bbs2-0061] stated that "quality evaluation was performed on the incorporated studies according to the \`Risk of bias´ Assessment Tool in the System Assessor Handbook 5.1.0 of Cochrane Collaboration update in March 2011". Nevertheless, the authors did not report results of this assessment. Additionally, [@CD009913-bbs2-0061] had some errors or inconsistencies, which made some results difficult to understand. For example:treatment regimens in the experimental group in several trials are not well described, because the drug delivered does not correspond to the treatment strategy for the same trial, according to the trial authors (in their Table 1);text related to their Figure 2 is not about sputum smear rate at EOT;[@CD009913-bbs2-0004] is mentioned twice in the references section.

We assessed the risk of bias of the included trials using the \'Risk of bias\' assessment tool and in accordance with the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD009913-bbs2-0044]), recorded the results in a standard table in RevMan ([@CD009913-bbs2-0050]), and summarized the findings in a \'Risk of bias\' table ([Figure 3](#CD009913-fig-0003){ref-type="fig"}) and a \'Risk of bias\' graph ([Figure 4](#CD009913-fig-0004){ref-type="fig"}). We summarized the quality of the evidence for the main outcomes, and reported the RCT data in \'Summary of findings\' tables ([Table 1](#CD009913-tbl-0001){ref-type="table"}; Summary of findings table 2).

Authors\' conclusions {#CD009913-sec1-0007}
=====================

This systematic review shows similar efficacy in relation to treatment failure, death, and sputum smear or culture conversion with the use of FDCs compared with single‐drug formulations. Although relapses were more common in people treated with FDCs, this was not statistically significant. FDCs and single‐drug formulations presented no differences with respect to acquisition of drug resistance, serious adverse events, or adverse effects leading to therapy discontinuation. These results come from trials that were mostly implemented under DOT.When deciding which is the most appropriate therapeutic scheme in a particular setting, efficacy and safety must be carefully weighed up in addition to other important factors, such as comfort of intake and patient convenience, which could increase treatment adherence and compliance. Based on these advantages, FDCs are strongly recommended by the WHO ([@CD009913-bbs2-0056]). In addition, FDCs may be more advisable than single‐drug formulations in settings where there is no DOT, in order to ensure treatment compliance and avoid resistance.The trials included in this Cochrane review had different definitions of the main outcomes, reporting standards, and also important drawbacks in methodological quality. The use of standard definitions for outcomes, standard approaches to report these outcomes, and improvement of the methodological quality is necessary for improving research in the TB area. The WHO has already defined treatment outcomes for TB patients ([@CD009913-bbs2-0056]; [@CD009913-bbs2-0058]) and, thus, can be a relevant reference to take into account.In this review, all but two included trials reported initial drug resistance and only two trials reported the HIV status of the participants. Future clinical trials that compare FDCs and single‐drug formulations should report a comparable baseline susceptibility test for the drugs used; this means they should report the initial resistance for all first‐line drugs allowing comparison of resistance results between clinical trials. Moreover, future trials should stratify their results by HIV status of participants. This would permit assessment of the outcomes in HIV‐seropositive populations and enable comparison with HIV‐negative people in future updates or evidence compilations.We identified one large clinical trial awaiting publication, [@CD009913-bbs2-0025], and we will update this review when its data are published. We also found four RCTs awaiting classification ([@CD009913-bbs2-0032]; [@CD009913-bbs2-0033]; [@CD009913-bbs2-0034]; [@CD009913-bbs2-0035]), whose data we will add based on their classification in the next review update.

CRG is a PhD candidate at the Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine Department, Universitat Autònoma de Barcelona, Spain. The editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this Cochrane review do not necessarily reflect UK government policy.
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Comparison 1Fixed‐dose combinations versus single‐drug formulations as available dataOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD009913-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 1 Treatment failure.73606Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[0.82, 2.00\][2 Relapse](#CD009913-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 2 Relapse.103621Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[1.00, 1.64\][3 Death](#CD009913-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 3 Death.114800Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.67, 1.39\][4 Sputum smear or culture conversion at 2 months of starting treatment](#CD009913-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.134836Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.99, 1.03\][5 Sputum smear or culture conversion at end of treatment (EOT)](#CD009913-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 5 Sputum smear or culture conversion at end of treatment (EOT).72319Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.96, 1.02\][6 Treatment adherence at 8 weeks of starting treatment](#CD009913-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 6 Treatment adherence at 8 weeks of starting treatment.3881Risk Ratio (M‐H, Random, 95% CI)1.04 \[0.96, 1.12\][7 Treatment adherence at EOT](#CD009913-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 7 Treatment adherence at EOT.51229Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.97, 1.06\][8 Acquisition of drug resistance](#CD009913-fig-00108){ref-type="fig"}Analysis 1.8Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 8 Acquisition of drug resistance.3491Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.15, 3.77\][9 Patient satisfaction](#CD009913-fig-00109){ref-type="fig"}Analysis 1.9Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 9 Patient satisfaction.2Risk Ratio (M‐H, Fixed, 95% CI)Subtotals only9.1 General satisfaction1222Risk Ratio (M‐H, Fixed, 95% CI)1.04 \[0.97, 1.12\]9.2 No problems on swallowing11023Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[1.00, 1.06\]9.3 Convenient number of tablets11045Risk Ratio (M‐H, Fixed, 95% CI)1.50 \[1.37, 1.64\]9.4 Acceptable taste11044Risk Ratio (M‐H, Fixed, 95% CI)1.39 \[1.27, 1.51\][10 Serious adverse events](#CD009913-fig-00110){ref-type="fig"}Analysis 1.10Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 10 Serious adverse events.63388Risk Ratio (M‐H, Fixed, 95% CI)1.45 \[0.90, 2.33\][11 Adverse events leading to discontinuation of therapy](#CD009913-fig-00111){ref-type="fig"}Analysis 1.11Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 11 Adverse events leading to discontinuation of therapy.135530Risk Ratio (M‐H, Random, 95% CI)0.96 \[0.56, 1.66\][12 Other adverse events](#CD009913-fig-00112){ref-type="fig"}Analysis 1.12Comparison 1 Fixed‐dose combinations versus single‐drug formulations as available data, Outcome 12 Other adverse events.94639Risk Ratio (M‐H, Fixed, 95% CI)0.85 \[0.72, 1.00\]

Comparison 2Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of biasOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD009913-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 1 Treatment failure.73606Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[0.82, 2.00\]1.1 High or unclear risk of selection bias51099Risk Ratio (M‐H, Fixed, 95% CI)1.77 \[0.67, 4.69\]1.2 Low risk of selection bias22507Risk Ratio (M‐H, Fixed, 95% CI)1.17 \[0.70, 1.93\][2 Relapse](#CD009913-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 2 Relapse.103621Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[1.00, 1.64\]2.1 High or unclear risk of selection bias81328Risk Ratio (M‐H, Fixed, 95% CI)2.84 \[1.34, 6.00\]2.2 Low risk of selection bias22293Risk Ratio (M‐H, Fixed, 95% CI)1.12 \[0.86, 1.46\][3 Death](#CD009913-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 3 Death.114800Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.67, 1.39\]3.1 High or unclear risk of selection bias92330Risk Ratio (M‐H, Fixed, 95% CI)0.86 \[0.57, 1.32\]3.2 Low risk of selection bias22470Risk Ratio (M‐H, Fixed, 95% CI)1.35 \[0.63, 2.93\][4 Sputum smear or culture conversion at 2 months of starting treatment](#CD009913-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.134836Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.99, 1.03\]4.1 High or unclear risk of selection bias112507Risk Ratio (M‐H, Fixed, 95% CI)1.04 \[1.01, 1.06\]4.2 Low risk of selection bias22329Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.95, 1.02\][5 Sputum smear or culture conversion at EOT](#CD009913-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 5 Sputum smear or culture conversion at EOT.72319Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.96, 1.02\]5.1 High or unclear risk of selection bias61160Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.98, 1.03\]5.2 Low risk of selection bias11159Risk Ratio (M‐H, Fixed, 95% CI)0.97 \[0.92, 1.03\][6 Acquisition of drug resistance](#CD009913-fig-00206){ref-type="fig"}Analysis 2.6Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 6 Acquisition of drug resistance.3491Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.15, 3.77\]6.1 High or unclear risk of selection bias2460Risk Ratio (M‐H, Fixed, 95% CI)0.64 \[0.08, 4.79\]6.2 Low risk of selection bias131Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.07, 15.57\][7 Serious adverse events](#CD009913-fig-00207){ref-type="fig"}Analysis 2.7Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 7 Serious adverse events.63388Risk Ratio (M‐H, Fixed, 95% CI)1.45 \[0.90, 2.33\]7.1 High or unclear risk of selection bias4685Risk Ratio (M‐H, Fixed, 95% CI)1.47 \[0.46, 4.71\]7.2 Low risk of selection bias22703Risk Ratio (M‐H, Fixed, 95% CI)1.44 \[0.86, 2.44\][8 Adverse events leading to discontinuation of therapy](#CD009913-fig-00208){ref-type="fig"}Analysis 2.8Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 8 Adverse events leading to discontinuation of therapy.135530Risk Ratio (M‐H, Random, 95% CI)0.96 \[0.56, 1.66\]8.1 High or unclear risk of selection bias112827Risk Ratio (M‐H, Random, 95% CI)0.67 \[0.31, 1.43\]8.2 Low risk of selection bias22703Risk Ratio (M‐H, Random, 95% CI)1.71 \[1.04, 2.81\][9 Other adverse events](#CD009913-fig-00209){ref-type="fig"}Analysis 2.9Comparison 2 Fixed‐dose combinations versus single‐drug formulations as available data: sensitivity analysis by risk of bias, Outcome 9 Other adverse events.94639Risk Ratio (M‐H, Fixed, 95% CI)0.85 \[0.72, 1.00\]9.1 High or unclear risk of selection bias71936Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.71, 1.07\]9.2 Low risk of selection bias22703Risk Ratio (M‐H, Fixed, 95% CI)0.82 \[0.63, 1.07\]

Comparison 3Fixed‐dose combinations versus single‐drug formulations: sensitivity analysis by intention‐to‐treat (ITT)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure (ITT analysis and all losses to follow‐up judged as failure)](#CD009913-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Fixed‐dose combinations versus single‐drug formulations: sensitivity analysis by intention‐to‐treat (ITT), Outcome 1 Treatment failure (ITT analysis and all losses to follow‐up judged as failure).74004Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[0.93, 1.14\][2 Relapse (ITT analysis and all losses to follow‐up judged as relapse)](#CD009913-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Fixed‐dose combinations versus single‐drug formulations: sensitivity analysis by intention‐to‐treat (ITT), Outcome 2 Relapse (ITT analysis and all losses to follow‐up judged as relapse).104716Risk Ratio (M‐H, Fixed, 95% CI)1.05 \[0.95, 1.16\][3 Sputum smear or culture conversion at 2 months of starting treatment (ITT analysis and all losses to follow‐up judged as conversion failure)](#CD009913-fig-00303){ref-type="fig"}Analysis 3.3Comparison 3 Fixed‐dose combinations versus single‐drug formulations: sensitivity analysis by intention‐to‐treat (ITT), Outcome 3 Sputum smear or culture conversion at 2 months of starting treatment (ITT analysis and all losses to follow‐up judged as conversion failure).135731Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.97, 1.03\][4 Sputum smear or culture conversion at EOT (ITT analysis and all losses to follow‐up judged as conversion failure)](#CD009913-fig-00304){ref-type="fig"}Analysis 3.4Comparison 3 Fixed‐dose combinations versus single‐drug formulations: sensitivity analysis by intention‐to‐treat (ITT), Outcome 4 Sputum smear or culture conversion at EOT (ITT analysis and all losses to follow‐up judged as conversion failure).72552Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.95, 1.02\]

Comparison 4Fixed‐dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatmentOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD009913-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Fixed‐dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 1 Treatment failure.73606Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[0.82, 2.00\]1.1 Fixed‐dose combinations (FDCs) only at intensive phase1307Risk Ratio (M‐H, Fixed, 95% CI)1.99 \[0.18, 21.69\]1.2 FDCs during all treatment63299Risk Ratio (M‐H, Fixed, 95% CI)1.26 \[0.80, 1.99\][2 Relapse](#CD009913-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Fixed‐dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 2 Relapse.103621Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[1.00, 1.64\]2.1 FDCs only at intensive phase1251Risk Ratio (M‐H, Fixed, 95% CI)3.94 \[1.13, 13.78\]2.2 FDCs during all treatment93370Risk Ratio (M‐H, Fixed, 95% CI)1.20 \[0.93, 1.55\][3 Death](#CD009913-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 Fixed‐dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 3 Death.114800Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.67, 1.39\]3.1 FDCs only at intensive phase1271Risk Ratio (M‐H, Fixed, 95% CI)1.40 \[0.50, 3.94\]3.2 FDCs during all treatment104529Risk Ratio (M‐H, Fixed, 95% CI)0.91 \[0.61, 1.35\][4 Sputum smear or culture conversion at 2 months of starting treatment](#CD009913-fig-00404){ref-type="fig"}Analysis 4.4Comparison 4 Fixed‐dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.134836Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.99, 1.03\]4.1 FDCs only at intensive phase1269Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.96, 1.07\]4.2 FDCs during all treatment124567Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.99, 1.03\][5 Acquisition of drug resistance](#CD009913-fig-00405){ref-type="fig"}Analysis 4.5Comparison 4 Fixed‐dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 5 Acquisition of drug resistance.3491Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.15, 3.77\]5.1 FDCs only at intensive phase1251Risk Ratio (M‐H, Fixed, 95% CI)0.36 \[0.01, 8.70\]5.2 FDCs during all treatment2240Risk Ratio (M‐H, Fixed, 95% CI)1.06 \[0.15, 7.24\][6 Adverse events leading to discontinuation of therapy](#CD009913-fig-00406){ref-type="fig"}Analysis 4.6Comparison 4 Fixed‐dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 6 Adverse events leading to discontinuation of therapy.135530Risk Ratio (M‐H, Random, 95% CI)0.96 \[0.56, 1.66\]6.1 FDCs only at intensive phase1271Risk Ratio (M‐H, Random, 95% CI)1.84 \[0.55, 6.15\]6.2 FDCs during all treatment125259Risk Ratio (M‐H, Random, 95% CI)0.87 \[0.48, 1.59\][7 Other adverse events](#CD009913-fig-00407){ref-type="fig"}Analysis 4.7Comparison 4 Fixed‐dose combinations (FDCs) administered only during intensive phase versus FDCs administered for the whole treatment, Outcome 7 Other adverse events.94639Risk Ratio (M‐H, Fixed, 95% CI)0.85 \[0.72, 1.00\]7.1 FDCs only at intensive phase1271Risk Ratio (M‐H, Fixed, 95% CI)1.05 \[0.75, 1.48\]7.2 FDCs during all treatment84368Risk Ratio (M‐H, Fixed, 95% CI)0.81 \[0.67, 0.97\]

Comparison 5Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phaseOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD009913-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 1 Treatment failure.73606Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[0.82, 2.00\]1.1 Daily medication for the whole treatment41517Risk Ratio (M‐H, Fixed, 95% CI)1.14 \[0.63, 2.06\]1.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase32089Risk Ratio (M‐H, Fixed, 95% CI)1.49 \[0.75, 2.96\][2 Relapse](#CD009913-fig-00502){ref-type="fig"}Analysis 5.2Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 2 Relapse.103621Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[1.00, 1.64\]2.1 Daily medication for the whole treatment71850Risk Ratio (M‐H, Fixed, 95% CI)1.12 \[0.83, 1.50\]2.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase31771Risk Ratio (M‐H, Fixed, 95% CI)1.72 \[1.07, 2.75\][3 Death](#CD009913-fig-00503){ref-type="fig"}Analysis 5.3Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 3 Death.114800Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.67, 1.39\]3.1 Daily medication for the whole treatment82859Risk Ratio (M‐H, Fixed, 95% CI)1.34 \[0.79, 2.29\]3.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase31941Risk Ratio (M‐H, Fixed, 95% CI)0.69 \[0.41, 1.16\][4 Sputum smear or culture conversion at 2 months of starting treatment](#CD009913-fig-00504){ref-type="fig"}Analysis 5.4Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.134836Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.99, 1.03\]4.1 Daily medication for the whole treatment93001Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.98, 1.03\]4.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase41835Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.99, 1.05\][5 Sputum smear or culture conversion at EOT](#CD009913-fig-00505){ref-type="fig"}Analysis 5.5Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 5 Sputum smear or culture conversion at EOT.72319Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.96, 1.02\]5.1 Daily medication for the whole treatment61961Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.96, 1.02\]5.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase1358Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.95, 1.05\][6 Acquisition of drug resistance](#CD009913-fig-00506){ref-type="fig"}Analysis 5.6Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 6 Acquisition of drug resistance.3491Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.15, 3.77\]6.1 Daily medication for the whole treatment1209Risk Ratio (M‐H, Fixed, 95% CI)1.05 \[0.07, 16.55\]6.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase2282Risk Ratio (M‐H, Fixed, 95% CI)0.64 \[0.09, 4.69\][7 Serious adverse events](#CD009913-fig-00507){ref-type="fig"}Analysis 5.7Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 7 Serious adverse events.63388Risk Ratio (M‐H, Fixed, 95% CI)1.45 \[0.90, 2.33\]7.1 Daily medication for the whole treatment41767Risk Ratio (M‐H, Fixed, 95% CI)1.60 \[0.95, 2.68\]7.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase21621Risk Ratio (M‐H, Fixed, 95% CI)0.79 \[0.21, 2.92\][8 Adverse events leading to discontinuation of therapy](#CD009913-fig-00508){ref-type="fig"}Analysis 5.8Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 8 Adverse events leading to discontinuation of therapy.135530Risk Ratio (M‐H, Random, 95% CI)0.96 \[0.56, 1.66\]8.1 Daily medication for the whole treatment93204Risk Ratio (M‐H, Random, 95% CI)0.78 \[0.39, 1.59\]8.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase42326Risk Ratio (M‐H, Random, 95% CI)1.55 \[0.74, 3.25\][9 Other adverse events](#CD009913-fig-00509){ref-type="fig"}Analysis 5.9Comparison 5 Daily regimen for the whole treatment versus daily regimen during the intensive phase followed by intermittent regimen during the continuation phase, Outcome 9 Other adverse events.94639Risk Ratio (M‐H, Fixed, 95% CI)0.85 \[0.72, 1.00\]9.1 Daily medication for the whole treatment62747Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.70, 1.02\]9.2 Daily medication at intensive phase followed by intermittent treatment at continuation phase31892Risk Ratio (M‐H, Fixed, 95% CI)0.86 \[0.64, 1.18\]

Comparison 6Supervised treatment versus self‐administered treatment during the intensive phaseOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD009913-fig-00601){ref-type="fig"}Analysis 6.1Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 1 Treatment failure.62447Risk Ratio (M‐H, Fixed, 95% CI)1.46 \[0.75, 2.84\]1.1 Supervised treatment during the intensive phase41962Risk Ratio (M‐H, Fixed, 95% CI)1.27 \[0.56, 2.89\]1.2 Self‐administered treatment during the intensive phase2485Risk Ratio (M‐H, Fixed, 95% CI)1.89 \[0.59, 6.04\][2 Relapse](#CD009913-fig-00602){ref-type="fig"}Analysis 6.2Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 2 Relapse.92676Risk Ratio (M‐H, Fixed, 95% CI)1.69 \[1.09, 2.63\]2.1 Supervised treatment during the intensive phase62318Risk Ratio (M‐H, Fixed, 95% CI)1.52 \[0.94, 2.45\]2.2 Self‐administered treatment during the intensive phase3358Risk Ratio (M‐H, Fixed, 95% CI)2.93 \[0.89, 9.59\][3 Death](#CD009913-fig-00603){ref-type="fig"}Analysis 6.3Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 3 Death.103678Risk Ratio (M‐H, Fixed, 95% CI)0.82 \[0.55, 1.22\]3.1 Supervised treatment during the intensive phase62503Risk Ratio (M‐H, Fixed, 95% CI)0.89 \[0.50, 1.58\]3.2 Self‐administered treatment during the intensive phase41175Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.44, 1.32\][4 Sputum smear or culture conversion at 2 months of starting treatment](#CD009913-fig-00604){ref-type="fig"}Analysis 6.4Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 4 Sputum smear or culture conversion at 2 months of starting treatment.123677Risk Ratio (M‐H, Fixed, 95% CI)1.03 \[1.01, 1.05\]4.1 Supervised treatment during the intensive phase82584Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.99, 1.05\]4.2 Self‐administered treatment during the intensive phase41093Risk Ratio (M‐H, Fixed, 95% CI)1.06 \[1.01, 1.11\][5 Sputum smear or culture conversion at EOT](#CD009913-fig-00605){ref-type="fig"}Analysis 6.5Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 5 Sputum smear or culture conversion at EOT.61160Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.98, 1.03\]5.1 Supervised treatment during the intensive phase2513Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.99, 1.04\]5.2 Self‐administered treatment during the intensive phase4647Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.97, 1.03\][6 Treatment adherence at 8 weeks of starting treatment](#CD009913-fig-00606){ref-type="fig"}Analysis 6.6Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 6 Treatment adherence at 8 weeks of starting treatment.3881Risk Ratio (M‐H, Random, 95% CI)1.04 \[0.96, 1.12\]6.1 Supervised treatment during the intensive phase1142Risk Ratio (M‐H, Random, 95% CI)1.01 \[0.97, 1.06\]6.2 Self‐administered treatment during the intensive phase2739Risk Ratio (M‐H, Random, 95% CI)1.09 \[0.90, 1.31\][7 Treatment adherence at EOT](#CD009913-fig-00607){ref-type="fig"}Analysis 6.7Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 7 Treatment adherence at EOT.51229Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.97, 1.06\]7.1 Supervised treatment during the intensive phase196Risk Ratio (M‐H, Fixed, 95% CI)1.04 \[0.97, 1.11\]7.2 Self‐administered treatment during the intensive phase41133Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.96, 1.06\][8 Serious adverse events](#CD009913-fig-00608){ref-type="fig"}Analysis 6.8Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 8 Serious adverse events.52266Risk Ratio (M‐H, Fixed, 95% CI)1.10 \[0.46, 2.60\]8.1 Supervised treatment during the intensive phase42056Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.40, 2.44\]8.2 Self‐administered treatment during the intensive phase1210Risk Ratio (M‐H, Fixed, 95% CI)3.17 \[0.13, 77.05\][9 Adverse events leading to discontinuation of therapy](#CD009913-fig-00609){ref-type="fig"}Analysis 6.9Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 9 Adverse events leading to discontinuation of therapy.124408Risk Ratio (M‐H, Random, 95% CI)0.82 \[0.43, 1.57\]9.1 Supervised treatment during the intensive phase83121Risk Ratio (M‐H, Random, 95% CI)0.44 \[0.11, 1.71\]9.2 Self‐administered treatment during the intensive phase41287Risk Ratio (M‐H, Random, 95% CI)1.06 \[0.55, 2.04\][10 Other adverse events](#CD009913-fig-00610){ref-type="fig"}Analysis 6.10Comparison 6 Supervised treatment versus self‐administered treatment during the intensive phase, Outcome 10 Other adverse events.83517Risk Ratio (M‐H, Fixed, 95% CI)0.82 \[0.68, 1.00\]10.1 Supervised treatment during the intensive phase72979Risk Ratio (M‐H, Fixed, 95% CI)0.79 \[0.64, 0.96\]10.2 Self‐administered treatment during the intensive phase1538Risk Ratio (M‐H, Fixed, 95% CI)2.56 \[0.90, 7.23\]

Comparison 7Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phaseOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment failure](#CD009913-fig-00701){ref-type="fig"}Analysis 7.1Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 1 Treatment failure.73606Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[0.82, 2.00\]1.1 Four drugs as FDCs during the intensive phase32941Risk Ratio (M‐H, Fixed, 95% CI)1.27 \[0.80, 2.01\]1.2 Three or 2 drugs as FDCs during the intensive phase4665Risk Ratio (M‐H, Fixed, 95% CI)1.52 \[0.26, 9.08\][2 Relapse](#CD009913-fig-00702){ref-type="fig"}Analysis 7.2Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 2 Relapse.93523Risk Ratio (M‐H, Fixed, 95% CI)1.28 \[1.00, 1.64\]2.1 Four drugs as FDCs during the intensive phase42675Risk Ratio (M‐H, Fixed, 95% CI)1.18 \[0.91, 1.54\]2.2 Three or 2 drugs as FDCs during the intensive phase5848Risk Ratio (M‐H, Fixed, 95% CI)2.55 \[1.07, 6.06\][3 Death](#CD009913-fig-00703){ref-type="fig"}Analysis 7.3Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 3 Death.114800Risk Ratio (M‐H, Fixed, 95% CI)0.96 \[0.67, 1.39\]3.1 Four drugs as FDCs during the intensive phase43002Risk Ratio (M‐H, Fixed, 95% CI)0.79 \[0.48, 1.30\]3.2 Three or 2 drugs as FDCs during the intensive phase71798Risk Ratio (M‐H, Fixed, 95% CI)1.21 \[0.70, 2.10\][4 Adverse events leading to discontinuation of therapy](#CD009913-fig-00704){ref-type="fig"}Analysis 7.4Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 4 Adverse events leading to discontinuation of therapy.135530Risk Ratio (M‐H, Random, 95% CI)0.96 \[0.56, 1.66\]4.1 Four drugs as FDCs during the intensive phase43430Risk Ratio (M‐H, Random, 95% CI)1.21 \[0.53, 2.78\]4.2 Three or 2 drugs as FDCs during the intensive phase92100Risk Ratio (M‐H, Random, 95% CI)0.81 \[0.37, 1.77\][5 Sputum smear or culture conversion at EOT](#CD009913-fig-00705){ref-type="fig"}Analysis 7.5Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 5 Sputum smear or culture conversion at EOT.72319Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.96, 1.02\]5.1 Four drugs as FDCs during the intensive phase21517Risk Ratio (M‐H, Fixed, 95% CI)0.98 \[0.94, 1.02\]5.2 Three or 2 drugs as FDCs during the intensive phase5802Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.98, 1.03\][6 Acquisition of drug resistance](#CD009913-fig-00706){ref-type="fig"}Analysis 7.6Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 6 Acquisition of drug resistance.3491Risk Ratio (M‐H, Fixed, 95% CI)0.76 \[0.15, 3.77\]6.1 Four drugs as FDCs during the intensive phase131Risk Ratio (M‐H, Fixed, 95% CI)1.07 \[0.07, 15.57\]6.2 Three or 2 drugs as FDCs during the intensive phase2460Risk Ratio (M‐H, Fixed, 95% CI)0.64 \[0.08, 4.79\][7 Serious adverse events](#CD009913-fig-00707){ref-type="fig"}Analysis 7.7Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 7 Serious adverse events.63388Risk Ratio (M‐H, Fixed, 95% CI)1.45 \[0.90, 2.33\]7.1 Four drugs as FDCs during the intensive phase32996Risk Ratio (M‐H, Fixed, 95% CI)1.34 \[0.81, 2.23\]7.2 Three or 2 drugs as FDCs during the intensive phase3392Risk Ratio (M‐H, Fixed, 95% CI)2.59 \[0.59, 11.34\][8 Sputum smear or culture conversion at 2 months of starting treatment](#CD009913-fig-00708){ref-type="fig"}Analysis 7.8Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 8 Sputum smear or culture conversion at 2 months of starting treatment.134836Risk Ratio (M‐H, Fixed, 95% CI)1.01 \[0.99, 1.03\]8.1 Four drugs as FDCs during the intensive phase42980Risk Ratio (M‐H, Fixed, 95% CI)1.00 \[0.97, 1.03\]8.2 Three or 2 drugs as FDCs during the intensive phase91856Risk Ratio (M‐H, Fixed, 95% CI)1.04 \[1.01, 1.07\][9 Other adverse events](#CD009913-fig-00709){ref-type="fig"}Analysis 7.9Comparison 7 Trials with four drugs as fixed‐dose combinations (FDCs) versus trials with three or two drugs as FDCs during the intensive phase, Outcome 9 Other adverse events.94639Risk Ratio (M‐H, Fixed, 95% CI)0.85 \[0.72, 1.00\]9.1 Four drugs as FDCs during the intensive phase32996Risk Ratio (M‐H, Fixed, 95% CI)0.81 \[0.64, 1.02\]9.2 Three or 2 drugs as FDCs during the intensive phase61643Risk Ratio (M‐H, Fixed, 95% CI)0.90 \[0.71, 1.13\]

We updated references in the [Background](#CD009913-sec1-0002){ref-type="sec"} section and added the latest World Health Organization (WHO) report ([@CD009913-bbs2-0060]) and the last version of the International Standard of Tuberculosis Care (ISTC) ([@CD009913-bbs2-0045]). Both documents were published after the Cochrane protocol, [@CD009913-bbs2-0063], was published.

In the [Methods](#CD009913-sec1-0004){ref-type="sec"} section, we redefined some aspects.

Types of intervention: for this review we considered that all drugs should be used ideally for a minimum of two months, but should not exceed nine months. We clarified the inclusion of studies with at least 60% of participants treated with each drug for a minimum of two months, although the rest of the participants had been treated only for one month with at least one of the drugs used.Types of outcome measures: for primary outcomes (especially treatment failure and relapse) we considered the definitions suggested by trial authors instead of the WHO\'s definitions, due to different definitions given in each trial. Differences in definitions can be justified by the wide range in the publication years of included studies (1987 to 2015). We clarified the definitions as suggested by the trial authors ([Table 9](#CD009913-tbl-0009){ref-type="table"}). For sputum smear or culture conversion, we took culture data instead of sputum smear data when both were available. We added \'patient satisfaction\' as a secondary outcome and we also clarified that data for death included all reported causes of death (see [Types of outcome measures](#CD009913-sec3-0005){ref-type="sec"}).Assessment of heterogeneity: we clearly redacted this section to better explain the methodology we used.Data synthesis: we did the main analysis with \'available data\', according to data given in the included trials.We performed a sensitivity analysis as an intention‐to‐treat analysis and we assumed all losses to follow‐up as a negative outcome for the primary dichotomous outcomes relating to treatment efficacy (treatment failure and relapse). Losses were not taken into account for the analysis of sputum smear or culture conversion.

We added data of baseline drug susceptibility to the \'[Characteristics of included studies](#CD009913-sec2-0019){ref-type="sec"}\' section, when available.

In addition, we performed the analyses using RevMan ([@CD009913-bbs2-0050]). We also assessed the quality of the evidence using the GRADE approach.

Characteristics of included studies \[ordered by study ID\] {#CD009913-sec2-0019}
===========================================================

[@CD009913-bbs2-0001]Methods**Design**: open, multicentre, multinational RCT\
**Generation of allocation**: generated by computer by an independent central randomization institute\
**Allocation concealment**: sealed, serially numbered, opaque randomization envelopes\
**Blinding**: none\
**Duration**: not mentionedParticipants**Number of participants**: 1159 randomized **Males**: 68% (per‐protocol population) **Inclusion criteria**: new pulmonary tuberculosis (TB) participants, aged 15 years or more with at least 2 sputum specimens positive for acid‐fast bacilli (AFB) on direct smear microscopy or 1 sputum specimen positive for AFB on direct microscopy and postero‐anterior chest X‐ray consistent with pulmonary TB; with written informed consent form to participate in the study and willingness to comply with the protocol **Exclusion criteria**: a body weight \< 30 kg, known or suspected hypersensitivity to rifamycins and/or to isoniazid, and/or to pyrazinamide and/or to etambutol hydrochloride and/or any of excipients; history of drug‐induced hepatitis; suspected or known as case of acute and chronic liver disease regardless of their origin; suspected or known as case of renal failure; suspected or known as case of peripheral optic neuritis, acute gouty arthritis (on clinical diagnosis), or history of gout; TB meningitis; any conditions (except HIV infection) that might prove fatal during the study (for example, metastatic cancer); poor general condition requiring additional measures to ensure survival; immunosuppressive treatment (for example, corticosteroids) during the whole study period; history of alcohol or drug abuse and history of psychiatric illness likely to lead to uncooperative behaviour, or pregnancy\
**Completeness of follow‐up**: 60.7% of participants (per‐protocol population)\
**Baseline drug susceptibility test**: results not reported **HIV status**: included only 6 HIV‐positive participants; 1 in the 4FDCs group and 5 in the single‐drug formulations groupInterventionsSix months treatment regimen (2HRZE/4HR)\
**Intervention: 4 fixed‐dose combinations (FDCs)**\
FDC tablets: Rimstar® (isoniazid 75 mg, rifampicin 150 mg, pyrazinamide 400 mg, and ethambutol 275 mg per tablet) given for the first 2 months (intensive phase), followed by Rimactazid® (isoniazid 75 mg and rifampicin 150 mg) for the succeeding 4 months (continuation phase) (N = 582).\
**Doses used**: \"on the basis of body weight according to the international recommendations (WHO and International Union Against Tuberculosis and Lung Disease \[The Union\])\" ([@CD009913-bbs2-0040])\
**Control**\
Single formulations of the same drugs in both phases (intensive and continuation) (N = 577).\
**Doses used**: the trial authors stated: \"according to the national treatment standards of each respective country\" The mean daily dosage of H, Z, and E at intensive phase in FDCs group was lower compared with single‐drug formulations group, the R dose were similar in both groups.\
Drugs were taken daily and according to the body weight for the total of participants, for whole treatment\
Mode of drugs administration: it was not reported whether the treatment was self‐administered or supervisedOutcomes**Outcomes used in this review**\
Sputum smear conversion rate at 2 and at 6 months after initiation of treatment.Treatment failure.Relapse rate at months 12.Adverse events: serious; those leading to discontinuation of therapy and other adverse events.Death.Patient satisfaction with tablets: problems on swallowing, convenient number of tablets, and acceptable taste.Notes**Locations**: Egypt, Indian, Pakistan, the Philippines, and Thailand\
**Setting**: not described\
**Source of funding**: not mentioned\
**Comments**: follow‐up duration was 12 months after initiation of treatment. Sputum smear conversion rate was measured at 2, 4, 6, 9, and 12 months after initiation of treatment. Adverse events were assessed at each visit. Participant satisfaction with tablets was noted at 2 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskUsing a computer random number generator.Allocation concealment (selection bias)Low riskCentral randomization institute which provided sequentially numbered, opaque, sealed envelopes.Blinding of participants and personnel (performance bias) All outcomesLow riskNo blinding, but outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesLow riskMissing outcome data balanced in numbers across intervention groups, with similar reasons for missing data.Selective reporting (reporting bias)Low riskMost of expected outcomes are included in the published report.Other biasLow riskThe study appears to be free of other sources of bias.[@CD009913-bbs2-0002]Methods**Design**: RCT\
**Generation of allocation**: not stated\
**Allocation concealment**: not stated\
**Blinding**: not stated\
**Duration**: not mentionedParticipants**Number of participants**: 250 randomized\
**Males**: 74% (of 196 participants initially sensitive to isoniazid)\
**Inclusion criteria**: new pulmonary TB participants (aged 15 or more) confirmed by chest x‐ray and sputum smear. They should lived in Algiers and accepted medical monitoring for 2 years\
**Exclusion criteria**: not reported\
**Completeness of follow‐up**: 86% (ITT population)\
**Baseline drug susceptibility test**: initially drug resistant participants 8.4% (16/190 tested); (FDCs H:2, S:4, H&S:4 and single‐drug formulations H:2, S:2, H&S:4)\
**HIV status of participants**: not reportedInterventionsSix months treatment regimen (2HRZ/4HR)\
**Intensive phase** (8 weeks)\
**Intervention**\
3FDCs (isoniazid 50 mg, rifampicin 120 mg and pyrazinamide 300 mg per tablet) (N = 124).\
**Doses used**: 4 tablets for participants weighing less than 44 kg, 5 tablets for participants weighing 44 to 50 kg and 6 tablets for participants weighing ≥ 50 kg\
**Control**\
The same drugs as single formulations (N = 126).\
**Doses used**: isoniazid 300 mg; rifampicin 450 mg for participants weighing \< 50 kg and 600 mg for ≥ 50 kg; and pyrazinamide 1500 mg for participants weighing \< 50 kg and 2000 mg for ≥ 50 kg\
**Continuation phase** (20 weeks)\
2FDCs (isoniazid and rifampicin) for all participants: 3 tablets (isoniazid 100 mg and rifampicin 150 mg per tablet) for participants weighing \< 50 kg and 2 tablets (isoniazid 150 mg and rifampicin 300 mg per tablet) for participants weighing \> 50 kg.\
Treatment was administered daily for the whole course, as directly observed treatment (DOT) with participants kept at hospital under supervision of health personnel at the beginning of intensive phase and as outpatients and self‐administered the rest of the timeOutcomes**Outcomes used in this review**\
Culture conversion at 2 months after initiation of treatment.Treatment failure.Relapse.Adverse events: those leading to discontinuation of therapy and other adverse events.Acquisition of drug resistance.Treatment adherence.General satisfaction with formulations.NotesThree publications for the same clinical trial ([@CD009913-bbs2-0036]; [@CD009913-bbs2-0039]; [@CD009913-bbs2-0002]). Most outcomes were assessed according to the data provided in [@CD009913-bbs2-0002], the most recent publication. Preliminary results had been previously published ([@CD009913-bbs2-0036]; [@CD009913-bbs2-0039])\
**Location**: Algeria\
**Setting**: The Matiben Chest Clinic at the West Algiers University Teaching Hospital and 3 other outpatient clinics in Algiers\
**Source of funding**: National Institute of Higher Medical Sciences in Algiers and the Ministry of Health\
**Comments** follow‐up duration was 2 years after initiation of treatment. Sputum smears and culture were examined at 8, 24, and 28 weeks, and every 6 months (follow‐up) after initiation of treatment. Adverse events were assessed at each visit and at 2 months. For the treatment adherence time to follow‐up was not reported. Patient satisfaction with formulations was noted at 2 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskInsufficient information about random sequence generation process to permit judgement of 'low risk' or 'high risk'.Allocation concealment (selection bias)Unclear riskInsufficient information to permit judgment of 'low risk' or 'high risk'.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding participants and personnel to the intervention, when the study did not specify blinding methods we considered it as an open design. In addition, outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesHigh riskReasons for missing outcome data were not reported.Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement of 'low risk' or 'high risk'.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0003]Methods**Design**: open multicentre RCT\
**Generation of allocation sequence**: not stated\
**Allocation concealment**: not stated\
**Blinding**: none\
**Duration**: 4 years and 5 months (from October 1981 to March 1986)Participants**Number of participants**: 701 randomized\
**Males**: 27.8% (protocol population)\
**Inclusion criteria**: adults, newly diagnosed with pulmonary TB due to *Mycobacterium tuberculosis* and freely consenting to participate in the trial\
**Exclusion criteria**: not reported\
**Completeness of follow‐up**: 87.2% (of 538 \"eligible patients\")\
**Baseline drug susceptibility test**: initially drug resistant participants 4.6% (32/701 randomized); FDCs: 13 and single‐drug formulations: 19. Also 56 participants with \"likelihood of initial isoniazid resistance\" of \"eligible patients\": FDCs: 28 and single‐drug formulations: 28\
**HIV status of participants**: not reportedInterventionsSix months treatment regimen (2HRZ/4HR)\
**Intervention**\
3FDCs tablets Rifater® (isoniazid 75 mg, rifampicin 150 mg and pyrazinamide 400 mg per tablet) given for the first 2 months, followed by 2FDCs tablets Rifamate® (isoniazid and rifampicin) for the next 4 months (N = 169).\
**Doses used**: 3 tablets for participants weighing \< 50 kg, 4 tablets for participants weighing 50 to 70 kg and 5 tablets for participants weighing \> 70 kg during the intensive phase. Doses given during continuation phase were not reported\
**Control**\
The same drugs given as separate formulations (N = 532).\
**Doses used**: not reported\
For whole treatment, drugs were taken daily and self‐administered as outpatients in both groupsOutcomes**Outcomes used in this review**\
Sputum conversion at 8 weeks after initiation of treatment.Adverse drug reactions: those leading to discontinuation of therapy and other adverse events.Compliance.Death.Notes**Location**: USA\
**Setting**: TB clinics\
**Source of funding**: not mentioned\
**Comments**: follow‐up duration was 2 years after completion of treatment. Time of assessment of reported outcomes: \"during the first 8 weeks of therapy\"***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskInsufficient information about random sequence generation process to permit a judgement of 'low risk' or 'high risk'.Allocation concealment (selection bias)Unclear riskInsufficient information to permit judgment of 'low risk' or 'high risk'.Blinding of participants and personnel (performance bias) All outcomesLow riskNo blinding, but outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding, but outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesHigh riskThe reason for missing outcome data is likely to be related to true outcome, with either imbalance in numbers for missing data across intervention and control groups.Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement of 'low risk' or 'high risk'.Other biasHigh riskThe trial was designed with the amended protocol of a former study and followed an unbalanced randomization scheme (60% of participants were randomized to the FDCs regimen and 20% to each of the 2 original treatment arms).[@CD009913-bbs2-0004]Methods**Design**: parallel‐group, open‐label, non inferiority, multicentre RCT\
**Generation of allocation sequence**: using a computer random number generator\
**Allocation concealment**: by sealed opaque envelopes with a serial number and details of treatment regimen\
**Blinding**: none\
**Duration**: 5 years (from 2003 to 2008)Participants**Number of participants**: 1585 randomized\
**Males**: 66.6% (per‐protocol population)\
**Mean age**: 34 years (SD: 13.5) (protocol population)\
**Inclusion criteria**: newly diagnosed pulmonary TB adults (aged 18 years or more) with 2 sputum specimens positive for acid‐fast bacilli on direct‐smear microscopy, had received either no previous anti‐TB chemotherapy or \< 4 weeks of chemotherapy for the current disease episode, had a firm home address that is readily accessible for visiting for the total duration of the trial (including follow‐up period), and had provided written informed consent form to participate in the study\
**Exclusion criteria**: had tuberculous meningitis or other extrapulmonary disease, insulin‐dependent diabetes, chronic liver or kidney disease, blood disorders, peripheral neuritis; were know to be pregnant or were breast feeding; had a history of psychiatric illness or alcoholism; or had any contraindication to any medications used in the study. Participants with no positive culture result at entry or rifampicin resistance before treatment were excluded postrandomization\
**Completeness of follow‐up**: 85% (participants included at modified intention‐to‐treat (ITT) analysis at 18 months)\
**Baseline drug susceptibility test**: initially isoniazid‐resistant isolates participants 11.2% (127/1132 with initial result), FDCs: 65 and single‐drug formulations: 62\
**HIV status of participants**: reported (HIV positive N = 77)Interventions26‐week treatment regimen (8HRZE/18HR)\
**Intensive phase** (8 weeks of daily treatment)\
**Intervention**\
4FDCs (isoniazid 75 mg, rifampicin 150 mg, pyrazinamide 400 mg and ethambutol 275 mg per tablet) (N = 798).\
**Doses used**:\
2 tablets for participants weighing 30 to 37 kg, 3 tablets for participants weighing 38 to 54 kg, 4 tablets for participants weighing 55 to 70 kg, and 5 tablets for patients weighing \> 70 kg\
**Control**:\
The same drugs as single formulations with isoniazid 100 mg, rifampicin 150 mg, pyrazinamide 400 mg, and ethambutol 400 mg per tablet (N = 787).\
**Doses used**\
For participants weighing 30 to 37 kg H: 1.5; R: 2; Z: 2, and E: 1.5 tablets\
Participants weighing 38 to 54 kg H: 2.5; R: 3; Z: 3, and E: 2 tablets\
Participants weighing 55 to 70 kg H: 3; R: 4; Z: 4, and E: 3 tablets\
Participants weighing \> 70 kg H: 3.5; R: 5; Z: 5, and E: 3.5 tablets\
**Continuation phase** (18 weeks of 3 times weekly treatment):\
2FDCs (isoniazid 150 mg and rifampicin 150 mg) for all participants.\
**Doses used**: 2\
tablets for participants weighing 30 to 37 kg, 3 tablets for participants weighing 38 to 54 kg, 4 tablets for participants weighing 55 to 70 kg, and 5 tablets for participants weighing \>70 kg\
The trial authors stated: \"Patients were required to attend the treatment facility daily during the initial phase (first 8 weeks) and then 3 times weekly during the continuation phase. Every treatment dose was to be taken under supervision of a member of the medical staff as DOT\". In most trial centres, DOT was done 6 days a week and on Sundays treatment intake was checked by health workers through unplanned visit to participants\' home and pill countsOutcomes**Outcomes used in this review**\
Culture conversion at 2 months after initiation of treatment.Treatment failure at 18 months.Relapse at 18 months.Adverse events in the first 2 months: serious, those leading to discontinuation of therapy and other adverse events.Acquisition of drug resistance.Death.\
**Outcomes reported and not used in this review**\
Unfavorable outcome: a combined endpoint of:bacteriological failure or relapse by 18 months after treatment initiation;treatment changed after 5 months because of 2 positive sputum smear results or a clinical or radiographic deterioration in the absence of bacteriological confirmation; anddeath, definitely or probably attributable to TB.Favorable response: sputum culture negative at 18 months (or 24 months, if the 18 months result was unavailable).NotesTwo publications for the same clinical trial ([@CD009913-bbs2-0004]; [@CD009913-bbs2-0049]). All outcomes were assessed according to the data provided in [@CD009913-bbs2-0004]. In [@CD009913-bbs2-0049] the assessment was done at 30 months after initiation of treatment and is the most recent publication, but the results confirm those found in [@CD009913-bbs2-0004] and the trial authors suggest that the follow‐up should be limited to 18 months after initiation of treatment in this kind of clinical trials\
**Locations**: Algeria, Bolivia, Colombia, Guinea, Mozambique, Nepal, Perú, Tanzania, and Vietnam\
**Setting**: \"clinical trial sites\" (different in each country)\
**Source of funding**: United States Agency for International Development\
**Comments**: follow‐up duration was 30 months after initiation of treatment. Participants were seen at the end of the second, third, fifth, and sixth month during treatment and then at 8, 10, 12, 15, 18, 24, and 30 months in the follow‐up phase. Adverse events was assess in each visit. Sputum sample was collected at each visit***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom allocations were computer generated.Allocation concealment (selection bias)Low riskSequentially numbered, opaque sealed envelopes were used.Blinding of participants and personnel (performance bias) All outcomesLow riskNo blinding, but the outcome is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but the outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesLow riskMissing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.Selective reporting (reporting bias)High riskMost primary and secondary outcomes were changed compared to the available protocol.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0005]Methods**Design**: RCT\
**Generation of allocation sequence**: not stated\
**Allocation concealment**: not stated\
**Blinding**: not stated\
**Duration**: 1 year and 1 month (from August 2001 to September 2002)Participants**Number of participants**: 40 randomized\
**Males**: 63.2% (per‐protocol population)\
**Age range**: 20 to 50 years\
**Inclusion criteria**: newly diagnosed pulmonary TB adults (aged 16 years or older) confirmed by sputum smear and culture; and freely consented to participate in the trial\
**Exclusion criteria**: presence of hepatic, renal, or hematological disorders that impose an individualization of dosage; presence of any type of ocular retro bulbar neuritis that may contraindicate ethambutol; pregnancy; presence of severe neuropsychiatric disorders, alcoholism, or other conditions that endanger the participant\'s life (cancer, HIV‐positive) and mean the participant is unlikely to complete the study; contacts of participants with TB with demonstrated resistant organisms; recurrences\
**Completeness of follow‐up**: 95% (ITT population)\
**Baseline drug susceptibility test** : initially drug resistant participants 0% (0/38 tested)\
**HIV status of participants**: not reportedInterventions6 months treatment regimen (2HRZE/4HR)\
**Intervention**\
2FDCs (isoniazid 150 mg and rifampicin 300 mg per tablet) during all treatment, complemented with pyrazinamide and ethambutol as single‐drug formulations in the intensive phase. In continuation phase isoniazid supplementary was done to achieve the dose of 10 mg/kg (N = 20).\
**Control**\
The same drugs, but in separate formulations (N = 20).\
**Doses used**: not reported.\
Treatment was administered as DOT in both groups, daily and admitted to the hospital during the intensive phase and 3 times per week as outpatients during the continuation phaseOutcomes**Outcomes used in this review**\
Culture conversion rate at 2 months after initiation of treatment.Adverse events: serious, those leading to discontinuation of therapy and other adverse events.\
**Outcomes reported and not used in this review**\
Therapeutic success rate at follow‐up.Notes**Location**: Romania\
**Setting**: hospital\
**Source of funding**: not mentioned\
**Comments**: the follow‐up duration was 1 year after initiation of treatment. Time for assessment of reported outcomes was not informed***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThere was insufficient information about the random sequence generation process.Allocation concealment (selection bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk'.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding the participants and personnel to the intervention, when the study did not provide specification of blinding methods, we considered it an open design.\
In addition, the outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but the outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesLow riskWe imputed missing data using appropriate methods.Selective reporting (reporting bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk'.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0006]Methods**Design**: RCT\
**Generation of allocation**: not stated\
**Allocation concealment**: serially numbered envelopes\
**Blinding**: not stated\
**Duration**: 1 year (from August 1986 to August 1987)Participants**Number of participants**: 229 randomized **Males**: 70% (of included population on final analysis) **Inclusion criteria**: new pulmonary TB patients, aged at least 15 years and weighing not less than 30 kg, without complications (TB or non‐TB) that could interfere with TB treatment **Exclusion criteria**: participants with \"poor condition or were moribund\" and \"cases with pleural effusion if the effusion obscured more than one third of lung field\"\
**Completeness of follow‐up**: 91.7% of participants (ITT population)\
**Baseline drug susceptibility test**: initially drug resistant participants 16.2% (34/210 tested) (H: 26, R: 5, H&R: 3; FDCs: 19, and single‐drug formulations: 15) **HIV status of participants**: not reportedInterventions26‐week treatment regimen (8HRZ/18HR)\
**Intervention**\
3FDCs tablets Rifater (isoniazid 80 mg, rifampicin 120 mg and pyrazinamide 250 mg per tablet) given for the first 8 weeks, followed by 2FDCs tablets Rifinah (isoniazid 100 mg and rifampicin 150 mg per tablet) for the next 18 weeks (N = 102).\
**Doses used**\
Intensive phase: 3 tablets for participants weighing 30 to 39.9 kg, 4 tablets for participants weighing 40 to 49.9 kg, and 5 tablets for participants weighing 50 to 60 kg\
Continuation phase: 3 tablets for participants weighing 30 to 39.9 kg, 3 tablets for participants weighing 40 to 49.9 kg and 4 tablets for participants weighing 50 to 60 kg\
**Control**:\
The same drugs given as separate formulations (N = 108).\
**Doses used** (mg/kg):\
**Intensive phase**\
For participants weighing 30 to 39.9 kg H: 7.5 to 10; R: 11.2 to 15; Z: 18.8 to 25\
Participants weighing 40 to 49.9 kg H: 6 to 7.5; R: 9 to 11.2; Z: 20 to 25\
Participants weighing 50 to 60 kg H: 6.6 to 8; R: 10 to 12; Z: 20.8 to 25\
**Continuation phase**\
For participants weighing 30 to 39.9 kg H: 7.5 to 10; R: 11.2 to 15\
participants weighing 40 to 49.9 kg H: 6 to 7.5; R: 9 to 11.2\
participants weighing 50 to 60 kg H: 6.6 to 8; R: 10 to 12\
Treatment was daily and self‐administered for the whole therapyOutcomes**Outcomes used in this review**\
Culture conversion rate at 8 and 26 weeks after initiation of treatment.Relapse rates 26 to 52 weeks after treatment initiation.Patient compliance at 8 and 26 weeks after treatment initiation.Adverse events: serious and those leading to discontinuation of therapy.Death.\
**Outcomes reported and not used in this review**\
Bio‐availability: serum levels of H, R, and Z.Acceptability of treatment.Notes**Locations**: India\
**Setting**: \"four centres\" (2 hospital and 2 ambulatory centres)\
**Source of funding**: \"Tata Pharma Indian Limited made available a free supply of Rifater, Rifinah, Ryrazinamide and Rifampicine\"\
**Comments**: follow‐up duration was 26 weeks after completion of treatment. Culture conversion rate and participant compliance were measured at 8 and 26 weeks after treatment initiation. Compliance was assessed by delay in drug collection and surprise pill counting. Participants were expected to collect their drugs every fortnight during the intensive phase and every month during the continuation phase. Time of assessment for the other outcomes was not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThere was insufficient information about the random sequence generation process to permit a judgement of 'low risk' or 'high risk'.Allocation concealment (selection bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk'.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding the participants and personnel to the intervention, when the study did not provide specification of blinding methods we was considered it an open design. In addition, the outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesUnclear riskThere was insufficient reporting of attrition/exclusions to permit a judgement of 'low risk' or 'high risk' (reasons for missing data provided but not disaggregated).Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement of 'low risk' or 'high risk'.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0007]Methods**Design**: RCT\
**Generation of allocation sequence**: \"by the method of random numbers\"\
**Allocation concealment**: not stated\
**Blinding**: not stated\
**Duration**: 2 years and 1 month (from October 1999 to November 2001)Participants**Number of participants**: 387 randomized\
**Males**: 58.9% (ITT population)\
**Inclusion criteria**: newly diagnosed pulmonary TB adults, aged from 16 to 50 years\
**Exclusion criteria**: not reported\
**Completeness of follow‐up**: not reported\
**Baseline drug susceptibility test**: initially drug resistant participants 4.9% (19/387 randomized)\
**HIV status of participants**: not reportedInterventionsFour months treatment regimen (4HRZE)\
Participants were randomly placed into 4 groups (groups 1 and 3 were intervention groups; and 2 and 4 control groups):\
**Group 1** received 4FDCs Mairin‐P (daily) (isoniazid 60 mg, rifampicin 120 mg, pyrazinamide 300 mg, and ethambutol 225 mg per tablet) + isoniazid tablet + streptomycin (N = 207). **Dose used:** FDCs was dosed by rifampicin, calculating it by 10 mg/kg of body weight, but not more than 6 tablets. Additional isoniazid was given at 5 mg/kg and streptomycin was dosed at 16 mg/kg.**Group 2** received the same drugs constituting Mairin‐P, but as single formulations + streptomycin (N = 92). **Dose used:** isoniazid 10 mg/kg, rifampicin 10 mg/kg, pyrazinamide 20 mg/kg, ethambutol 25 mg/kg, and streptomycin 16 mg/kg.**Group 3** received the same fixed‐combinations as group 1 (daily) without streptomycin (N = 51). **Dose used:** the same than group 1.**Group 4** received the same drugs than group 2 without streptomycin (N = 18). **Dose used**: the same than group 2.\
The mode of treatment administration was not reported for all participants, neither the frequency of treatment in control groups. The treatment was reported only for initial 4 months (intensive phase).\
The first and second groups were considered \"patients with advanced pulmonary TB\" and the third and fourth groups \"patients with pulmonary TB of limited localised spread\"OutcomesRate of disappearance of clinical symptoms of TB.Sputum conversion at 4 months after initiation of treatment.Cavity closure rate.Adverse events: those leading to discontinuation of therapy and other adverse events.\
We did not use all reported outcomes in this Cochrane review because losses were not imputed according to the intervention or control groupsNotes**Location**: Russia\
**Setting**: clinic\
**Souce of funding**: not mentioned\
**Comments**: follow‐up duration was 4 months after initiation of treatment, the time for assessment of the reported outcomes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom numbers method.Allocation concealment (selection bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk\'.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding the participants and personnel to the intervention, when the study did not provide specification of blinding methods we considered it an open design.\
In addition, outcomes were unlikely to be influenced by a lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but outcome measurement was not likely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesHigh riskThe reason for missing outcome data is likely to be related to the true outcome.Selective reporting (reporting bias)High riskThe trial report fails to include results for a key outcome that would be expected to have been reported.Other biasUnclear riskThere was insufficient information to assess whether there was an important risk of bias.[@CD009913-bbs2-0008]Methods**Design**: RCT\
**Generation of allocation sequence**: not stated\
**Allocation concealment**: not stated\
**Blinding**: not stated\
**Duration**: not mentionedParticipants**Number of participants**: 105 randomized\
**Males**: 88.6% (ITT population)\
**Inclusion criteria**: participants aged 18 years or more with active pulmonary TB, confirmed by sputum smear or culture or both, and with no history of previous TB treatment\
**Exclusion criteria**: not reported\
**Completeness of follow‐up**: 48.6% (ITT population)\
**Baseline drug susceptibility test**: initially drug resistant participants 23.5% (12/51 included in analysis); FDCs: 4 resistant to Z and single‐drug formulations: 2 resistant to E and 6 to Z\
**HIV status of participants**: not reportedInterventionsSix months treatment regimen (2HRZE/4HRE)\
**Intervention**\
FDCs tablets with Rifater® (isoniazid 50 mg, rifampicin 120 mg and pyrazinamide 250 mg per tablet) + etambuthol as single‐drug formulation for the first 2 months (intensive phase) followed by Rifinah® 150 (isoniazid 100 mg and rifampicin 150 mg per tablet) or Rifinah® 300 (isoniazid 150 mg and rifampicin 300 mg per tablet) + etambuthol as single‐drug formulation for 4 months (continuation phase) (N = 57).\
**Doses used**\
Rifater: 3 tablets for participants weighing 30 to 39 kg, 4 tablets for participants weighing 40 to 49 kg, and 5 tablets for participants weighing ≥ 50 kg\
Rifinah: 3 tablets of Rifinah 150 for participants weighing \< 50 kg, or 2 tablets of Rifinah 300 for participants weighing ≥50 kg\
The ethambutol dose was not reported\
**Control**\
The same drugs given as separate formulations (N = 48).\
**Doses used**\
Isoniazid 300 mg, rifampicin 450 mg, pyrazinamide 1500 mg, and etambuthol 1200 mg for participants weighing \< 50 kg during the first 2 months, followed by isoniazid 300 mg, rifampicin 450 mg, and etambuthol 800 mg for 4 months. The dosages for participants weighing ≥ 50 kg followed the same dosing schedule, except that rifampicin 600 mg was administered.\
For whole treatment, drugs were taken daily and self‐administered as outpatientsOutcomes**Outcomes used in this review**\
Sputum smear or culture conversion rate at 2 and 6 months after initiation of treatment.Treatment failure.Relapse.Patient compliance.Adverse reactions: those leading to discontinuation of therapy.Death.\
**Outcomes reported and not used in this review**\
Patient response to TB treatment (microbiological, clinical, and radiological improvement).Notes**Location**: Taiwan\
**Setting**: hospital (outpatient clinic at chest department)\
**Source of funding**: not mentioned\
**Comments**: follow‐up duration was 12 months after completion of treatment. Sputum specimens were examined monthly during therapy and after 3, 6, and 12 months of completion of treatment. Adverse events were assessed monthly. Relapse was assessed after 3, 6, and 12 months of completion of treatment or any time relapse was suspected. Patient compliance was evaluated by losses and regimen changes during treatment***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThere was insufficient information about random sequence generation process to permit a judgement of 'low risk' or 'high risk'.Allocation concealment (selection bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk'.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding the interventions for participants and personnel, when the study did not provide specification of blinding methods, we considered it an open design. In addition, the outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesLow riskMissing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.Selective reporting (reporting bias)Low riskThe trial authors included most of the expected outcomes in the published report.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0009]Methods**Design**: RCT\
**Generation of allocation**: not stated\
**Allocation concealment**: \"alternate allocation of eligible patients to each regimen to obtain equal number for both groups\"\
**Blinding**: not stated\
**Duration**: 2 years for [@CD009913-bbs2-0043] (from 1999 to 2001) and 2 months for [@CD009913-bbs2-0009] (from December 2004 to January 2005)Participants**Number of participants**: 434 randomized\
**Males**: 59.7% (ITT population)\
**Mean age**: 37.1 years (ITT population)\
**Inclusion criteria**: new smear‐positive TB participants with body weight between 33 and 50 kg and written informed consent form to participate in the trial\
**Exclusion criteria**: not reported\
**Completeness of follow‐up**: 63.1% (ITT population)\
**Baseline drug susceptibility test**: drug sensitivity test not performed (either at the beginning or during follow‐up)\
**HIV status of participants**: not reportedInterventionsFive months treatment regimen (2HRZE/3HR)\
**Intervention**\
4FDCs (isoniazid, rifampicin, pyrazinamide, and ethambutol) daily for 2 months during the intensive phase; followed by 2FDCs (isoniazid and rifampicin) 3 times per week for 3 months during the continuation phase (N = 236).\
**Doses used**\
Intensive phase: the average adult dose contained isoniazid 225 mg, rifampicin 450 mg, pyrazinamide 1200 mg, and ethambutol 825 mg\
Continuation phase: the averaged adult dose contained isoniazid 450 mg and rifampicin 450 mg\
**Control**:\
The same drugs as separate formulations (N = 198).\
**Doses used**\
Intensive phase: the average adult dose contained isoniazid 300 mg, rifampicin 450 mg, pyrazinamide 1500 mg, and ethambutol 750 mg\
Continuation phase: the average adult dose contained isoniazid 600 mg and rifampicin 450 mg\
Both FDCs and single‐drug formulations were given under direct supervision at health centres, once weekly during the intensive phase and fortnightly during the continuation phase. The remaining days, drugs were self‐administered at home. For all participants, the dose were adjusted to the body weightOutcomes**Outcomes used in this review**\
Sputum smear conversion at 2 and 5 to 6 months after initiation of treatment.Failure.Relapse.Death.\
**Outcomes reported and not used in this Cochrane review**\
Cured.NotesTwo publications for the same clinical trial ([@CD009913-bbs2-0043]; [@CD009913-bbs2-0009]). All outcomes but 1 (sputum smear conversion) were recorded with data found in [@CD009913-bbs2-0009], because it was the most recent document. Sputum smear conversion (at 2 and 6 months) was available only in the preliminary report ([@CD009913-bbs2-0043])\
**Location**: Republic of Indonesia\
**Setting**: \"health centres\"\
**Source of funding**: Royal Netherlands Tuberculosis Association\
**Comments**: follow‐up duration was not reported. Sputum smear conversion was examined at the beginning and at 2, 5, and 6 months from treatment initiation. Cured participants were followed up during 2004 to 2005 for relapse. The assessment for the other outcomes was not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskJudgement of personal or clinicians.Allocation concealment (selection bias)High riskAlternate allocation of eligible participants.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding the interventions for participants and personnel, when the study did not provide specification of blinding methods we considered it an open design. In addition, outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesHigh riskPotentially inappropriate application of simple imputation.Selective reporting (reporting bias)High riskThe trial report fails to include results for a key outcome that would be expected to have been reported for such a trial.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0010]Methods**Design**: RCT\
**Generation of allocation**: not stated\
**Allocation concealment**: not stated\
**Blinding**: not stated\
**Duration**: 3 years and 10 months (from October 1983 to August 1987)Participants**Number of participants**: 310 randomized\
**Males**: 66% (of 179 participants with drug‐susceptible bacilli on admission)\
**Inclusion criteria**: participants aged 15 years or more who had been newly diagnosed for pulmonary TB, with sputum smear positive for acid‐fast bacilli and yielded *M. tuberculosis* on culture\
**Exclusion criteria**: not reported\
**Completeness of follow‐up**: 81% (ITT population)\
**Baseline drug susceptibility test**: initially drug resistant participants 5.5% (17/307 treated)\
**HIV status of participants**: not reportedInterventionsSix months treatment regimen\
**Intervention and control groups**:\
**Intensive phase**:\
Regimen 1: isoniazid, rifampicin and pyrazinamide + streptomycin for 2 months (2SHRZ regimen).Regimen 2: the same regimen, but given for only 1 month (1SHRZ regimen).Regimen 3: the same as regimen 1 but without streptomycin (2HRZ regimen).\
The 3 regimens were given daily as FDCs or as separate formulations.\
Rifater (isoniazid 50 mg, rifampicin 120 mg, pyrazinamide 300 mg per tablet) was used as a FDC\
**Doses used**:\
Rifater\
4 tablets for participants weighing ≤ 42 kg.5 tablets for participants weighing 43 to 57 kg.6 tablets for participants weighing ≥ 58 kg.\
Regimens given as single‐drug formulations:\
H 300 mg, R 450 mg, Z 1500 mg.H 300 mg, R 600 mg, Z 1500 mg.H 300 mg, R 600 mg, Z 2000 mg.\
Streptomycin: 750 mg for the regimen 1 and 2 regardless of body weight\
**Continuation phase**: isoniazid and rifampin given 3 times a week as single‐drug formulation for both treatment groups (intervention and control)\
**Doses used**:\
Isoniazid:\
6 tablets (600 mg) for participants weighing ≤ 42 kg.8 tablets (800 mg) for participants weighing 43 to 57 kg.10 tablets (1000 mg) for participants weighing ≥ 58 kg.\
Rifampicin: 2 capsules (600 mg) for all participants\
Treatment was given as DOT for the whole treatmentOutcomes**Outcomes used in this review**\
Culture conversion at 2 months after initiation of treatment.Treatment failure.Relapse.Adverse events: those leading to discontinuation of therapy and other adverse events.Death.Acquisition of drug resistance.\
**Outcomes reported and not used in this review**\
Default.Complaints.NotesTwo publications of the same clinical trial ([@CD009913-bbs2-0052]; [@CD009913-bbs2-0010]). All outcomes were assessed according to the data provided in [@CD009913-bbs2-0010], because it is the most recent publication; except sputum conversion at 2 months and adverse events as these outcomes were available only in the preliminary report ([@CD009913-bbs2-0052]).\
**Location**: Singapore\
**Setting**: medical clinic\
**Source of funding**: not mentioned\
**Comments**: follow‐up duration was 5 years after initiation of treatment. A clinician performed a clinical evaluation on admission and monthly up to 18 months, then once every 3 months up to 30 months, and once every 6 months up to 5 years from the date of admission to the study. Five sputum smears were examined bacteriologically (smear and culture) before treatment; thereafter 1 specimen was examined monthly during the first 6 months, then 2 specimens were examined once every month up to 18 months and at each follow‐up visit up to 60 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThere was insufficient information about random sequence generation process to permit a judgement of 'low risk' or 'high risk'.Allocation concealment (selection bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk\'.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding participants and personnel to the intervention, when the trial did not specify blinding methods we considered it an open design.\
In addition, outcomes were unlikely to be influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesLow riskThe missing outcome data balanced in numbers across intervention groups with similar reasons for missing data.Selective reporting (reporting bias)Unclear riskThere was insufficient information to permit a judgement of \'low risk\' or \'high risk\'.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0011]Methods**Design**: open RCT\
**Generation of allocation**: used a random number table\
**Allocation concealment**: unclear\
**Blinding**: none\
**Duration**: 1 year, from October 2008 to November 2009Participants**Number of participants**: 161 randomized\
**Males**: 67.7% of ITT population\
**Inclusion criteria**: participants aged 18 years and older with suspected pulmonary TB (at least 2 sputum specimens positive for acid‐fast bacilli on direct smear microscopy or 1 positive specimen and a chest X‐ray or chest computed tomography (CT) scan consistent with pulmonary TB), as determined by a clinician\
**Exclusion criteria**: participants with a history of receiving anti‐TB treatment, had a life expectancy of \< 6 months, had abnormal baseline liver function (alanine aminotransferase or aspartate aminotransferase values \> 3 times the upper limit of normal or total bilirubin values \> 2 mg/dL, or both), or had received immunosuppressive treatment\
**Completeness of follow‐up**: 60.9% (ITT population)\
**Baseline drug susceptibility test**: initially drug resistant participants 3.1% (5/161 randomized participants)\
**HIV status of participants**: not reportedInterventionsSix months treatment regimen (2HRZE/4HRE)\
**Intervention**\
FDCs tablets with Rifater (isoniazid 80 mg, rifampicin 120 mg, and pyrazinamide 250 mg per tablet) + etambuthol as single‐drug formulations for the first 2 months (intensive phase) followed by Rifinah® 150 (isoniazid 100 mg and rifampicin 150 mg per tablet) or Rifinah® 300 (isoniazid 150 mg and rifampicin 300 mg per tablet) + etambuthol as single‐drug formulations for 4 months (continuation phase) (N = 75).\
**Doses used**:\
Rifater: 3 tablets for participants weighing 30 to 39 kg, 4 tablets for participants weighing 40 to 49 kg, and 5 tablets for participants weighing ≥ 50 kg\
Rifinah: 3 tablets of Rifinah 150 for participants weighing \< 50 kg or 2 tablets of Rifinah 300 for participants weighing ≥ 50 kg\
The ethambutol dose was not reported\
**Control**:\
The same drugs given as separate formulations (N = 86).\
**Doses used**: not reported. For whole treatment, drugs were taken daily. Treatment was given as directly‐observed treatments during work‐week and self‐administered during weekends.\
The trial authors state: \"a trained supervisor observed the participant during medication administration 5 days/week, whereas weekend doses were self‐administered. However, treatment intake was still checked by the supervisor by unplanned visits to participants' homes and by pill counting\"Outcomes**Outcomes used in this review**\
Culture conversion after 2 and 6 months of treatment initiation.Treatment failure.Relapse.Adverse events: serious and those leading to discontinuation of therapy.Death.\
**Outcomes reported and not used in this review**\
Culture conversion after 4 months of treatment initiation.Liver function fluctuation during anti‐TB drug treatment.Notes**Location**: Taiwan\
**Setting**: hospital\
**Source of funding**: by a grant (EDAHP99037) from E‐DA hospital/I‐Shou University, Kaohsiung, Taiwan\
**Comments**: follow‐up duration was 1 year after treatment completion. Sputum was collected from the participants at 2 and 4 months of treatment and at the end of treatment. Adverse effects were assessed at each visit during the first and second weeks of the first month of treatment and were then assessed monthly over the next 4 months. Relapse was assessed at the end of follow‐up***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskUsing a random number table.Allocation concealment (selection bias)Unclear riskThere was insufficient information to permit a judgment of 'low risk' or 'high risk'.Blinding of participants and personnel (performance bias) All outcomesLow riskNo blinding, but the outcomes were unlikely to be influenced by a lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but the outcome measurement is unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesHigh riskAll missing data were not reported.Selective reporting (reporting bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk'.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0012]Methods**Design**: RCT\
**Generation of allocation sequence**: unclear\
**Allocation concealment**: unclear\
**Blinding**: not stated\
**Duration**: not mentionedParticipants**Number of participants**: 293 randomized\
**Males**: 63.8% (ITT population)\
**Inclusion criteria**: participants aged between 15 to 55 years with sputum positive pulmonary TB, who gave consent to participate\
**Exclusion criteria**: participants with renal, hepatic, diabetic, and cardiac problems, and pregnancy\
**Completeness of follow‐up**: 70% (ITT population)\
**Baseline drug susceptibility test**: results not reported\
**HIV status of participants**: not reportedInterventionsSix months treatment regimen (2HRZE/4HRE): participants were randomly selected into 3 groups (A, B, and C)\
**Intervention** (groups A and B):\
1. **Group A** (N = 97)\
**Intensive phase**: 4FDCs (isoniazid 75 mg, rifampicin 120 mg, pyrazinamide 350 mg, and ethambutol 250 mg per tablet)\
**Doses used**: 4 tablets for participants weighing \< 50 kg and 5 tablets for participants weighing \> 50 kg\
**Continuation phase**: 3FDCs (isoniazid 100 mg, rifampicin 150 mg, and ethambutol 300 mg per tablet)\
**Doses used**: 3 tablets for participants weighing \< 50 kg and 4 tablets for participants weighing \> 50 kg\
2. **Group B** (N = 97)\
**Intensive phase**: 4FDCs (isoniazid 60 mg, rifampicin 120 mg, pyrazinamide 300 mg, and ethambutol 225 mg per tablet)\
**Doses used**: 4\
tablets for participants weighing \< 50 kg and 5 tablets for participants weighing \> 50 kg\
**Continuation phase**: 3FDCs (isoniazid 75 mg, rifampicin 150 mg, and ethambutol 300 mg per tablet)\
**Doses used**: 3\
tablets for participants weighing \< 50 kg and 4 tablets for participants weighing \> 50 kg\
**Control group**:\
Group C: the same drugs as single formulations (N = 99).\
**Intensive phase**\
Isoniazid 100 mg, rifampicin (150 mg and 450 mg capsules), pyrazinamide 500 mg, and ethambutol 400 mg\
**Doses used**:\
Participants weighing \< 50 kg: isoniazid 3 tablets, rifampicin (450 mg) 1 capsule, pyrazinamide 3 tablets, and ethambutol 3 tablets\
Participants weighing \> 50 kg: isoniazid 4 tablets, rifampicin 1 capsule 450 mg, + 1 capsule 150 mg, pirazinamide 4 tablets and ethambutol 4 tablets\
**Continuation phase**\
Isoniazid 100 mg, rifampicin (150 mg and 450 mg capsules) and ethambutol 400 mg\
**Doses used**:\
Participants weighing \< 50 kg: isoniazid 3 tablets, rifampicin (450 mg) 1 capsule and ethambutol 3 tablets\
Participants weighing \> 50 kg: isoniazid 4 tablets, rifampicin 1 capsule 450 mg + 1 capsule 150 mg, and ethambutol 4 tablets\
In all groups, treatment was administered daily, by DOT at the hospital for 2 months (during the intensive phase) and self‐administered at home for 4 months (during the continuation phase)Outcomes**Outcomes used in this review**\
Sputum smear conversion at 2 months after initiation of treatment.Relapse.Adverse events: serious; those leading to discontinuation of therapy and other adverse events.Death.Average days for sputum conversion.\
**Outcomes reported and not used in this review**\
Socio economic status: marital status, literacy, working status and geographic area (urban or rural).Laboratory examination (average of haemoglobin level improvement and average decrease of erythrocyte sedimentation rate).Average of weight increase.Chest X‐rays changes (average of chest X‐rays lesions decrease (at 2 months and between 2 and 6 months), and average decrease of the total lesions).Notes**Location**: Pakistan\
**Setting**: hospital\
**Source of funding**: not mentioned\
**Comments**: follow‐up duration was 6 months after treatment completion. Time for assessment of reported outcomes was not clearly informed. During the intensive phase participants were admitted to the hospital and during the continuation phase they self‐administered the treatment at home and returned to the hospital once a month for check‐up***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskDrawing of lots.Allocation concealment (selection bias)High riskAssignment envelopes were used without appropriate safeguards (\"sealed envelopes with group name in a bag from which the patient chose an envelope\").Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding the participants and personnel to the intervention, when the study did not specify the blinding methods, we considered it an open design.\
In addition, the outcomes were unlikely to be influenced by a lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but outcome measurement was unlikely to be influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesLow riskNo missing outcome data.Selective reporting (reporting bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk'.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0013]Methods**Desing**: RCT\
**Generation of allocation**: referring to a random number table\
**Allocation concealment**: not stated\
**Blinding**: not stated\
**Duration**: not mentionedParticipants**Number of participants**: 209 randomized\
**Males**: 64.4% (per‐protocol population)\
**Inclusion criteria**: newly diagnosed uncomplicated pulmonary TB adults (aged 15 or more) with sputum positive by both smear and culture\
**Exclusion criteria**: participants with extrapulmonary or miliary TB, severe impairment of hepatic or renal function, malignancy, a history of eye disease or hematologic problems, or gout; if they were pregnant, if they had taken corticosteroids or other immunosuppressive drugs; or if they had any other conditions that would introduce risk during chemotherapy\
**Completeness of follow‐up**: 98% (ITT population)\
**Baseline drug susceptibility test**: initially drug resistant participants 7.7% (13/169 tested).\
FDCs: 2 S, 2 H, 2 S+H, 1 S+H+R and single‐drug formulations: 1 S, 2 H, 1 R, 1 S+H, 1 S+E+R\
**HIV status of participants**: not reportedInterventionsSix months treatment regimen (2HRZ/4HR):\
**Intervention**\
3FDCs tablets: Rifater® (isoniazid 80 mg, rifampicin 120 mg, and pyracinamide 250 mg per tablet) for 2 months (intensive phase); followed by 2FDCs: Rifinah® (isoniazid 100 mg and rifampicin 150 mg or isoniazid 150 mg and rifampicin 300 mg) for the succeeding 4 months (continuation phase) (N = 104).\
**Doses used**\
Intensive phase: 3 tablets for participants weighing 30 to 39 kg, 4 tablets for participants weighing 40 to 49 kg, 5 tablets for participants weighing ≥ 50 kg\
Continuation phase: 3 tablets of Rifinah contained isoniazid 100 mg for participants weighing \< 50 kg and 2 tablets of Rifinah contained isoniazid 150 mg for participants weighing ≥ 50 kg\
**Control**:\
The same drugs as single formulations (N = 105).\
**Doses used**\
Intensive phase: participants weighing \< 50 kg: 3 isoniazid 100 mg tablets, 3 rifampicin 150 mg tablets, and 6 pirazinamide 250 mg tablets\
Continuation phase: participants weighing \< 50 kg: 3 isoniazid 100 mg tablets and 3 rifampicin 150 mg tablets; participants weighing ≥ 50 kg followed the same dosing schedule for intensive, with exception that 4 rifampicin 150 mg rather than 3\
All drugs were administered daily by DOT under \"supervision of a health care provider\" and participants were kept at hospital for both treatment groupsOutcomes**Outcomes used in this review**\
Culture conversion at 2 and 6 months after initiation of treatment.Relapse.Adverse reactions: those leading to discontinuation of therapy and other adverse events.Death.\
**Outcomes reported and not used in this review**\
Dosage compliance.Preference for participants: data were not imputed according to the intervention or control group (presented as a percentage for the total of participants).Preference of physicians, pharmacists, and administrators.Notes**Location**: urban districts and rural areas of Biijing, China\
**Setting**: hospital\
**Source of funding**: Hoechst Marion Roussel, Singapore\
**Comments**: follow‐up duration was 2 years after completion of treatment. During the 6 months of treatment, sputum smears were examined each month and cultures were examined at 2, 4, and 6 months. participants who had completed treatment and who had sputum conversion from positive to negative were followed with sputum smear at 3, 6, 9, 12, 15, and 24 months. Sputum cultures were tested at 6, 12, 18, and 24 months***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskReferred to a random number table.Allocation concealment (selection bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk'.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding the participants and personnel, when the study did not specify blinding methods we considered it an open design.\
In addition, the outcomes were unlikely to be influenced by a lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskThere was no blinding of outcome assessment, but outcome measurement was unlikely to be influenced by a lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesLow riskThere were few missing data from both treatment groups and the reasons of losses were reported.Selective reporting (reporting bias)Unclear riskThere was insufficient information to permit a judgement of \'low risk\' or \'high risk\'.Other biasLow riskThe trial appears to be free of other sources of bias.[@CD009913-bbs2-0014]Methods**Design**: RCT\
**Generation of allocation**: not stated\
**Allocation concealment**: not stated (with ratio of 2:1 in treatment and control groups)\
**Blinding**: not stated\
**Duration**: not mentionedParticipants**Number of participants**: 348 randomized **Males**: 70.1% (protocol population) **Inclusion criteria**: newly diagnosed pulmonary infiltrative TB participants, confirmed by sputum smear and chest X‐ray, aged 15 to 70 years and \> 40 kg **Exclusion criteria**: participants with serious heart, hepatic or renal diseases, and psychosis, epilepsy, or pregnant\
**Completeness of follow‐up**: 88.5% (ITT population)\
**Baseline drug susceptibility test**: initially drug resistant participants 14% (43/308 included in analysis). FDCs: 5 S, 13 H, 7 R, 6 H+R, 1 S+E, 3 S+H and single‐drug formulations: 1 S, 2 H, 2 R, 3 H+R\
**HIV status of participants**: not reportedInterventionsSix months treatment regimen (2HRZ/4HR)\
**Intervention**\
3FDCs tablets: Rifater® (isoniazid 80, rifampicin 120 mg, pyrazinamide 250 mg per tablet) for 2 months (intensive phase); followed by 2FDCs tablets: Rifinah® (A: isoniazid 100 mg and rifampicin 150 mg per tablet) and/or (B: isoniazid 150 and rifampicin 300 mg per tablet) for the succeeding 4 months (continuation phase) (N = 227).\
**Doses used**:\
Intensive phase: 4 tablets of Rifater for participants that weighed ≤ 60 kg and 5 tablets for participants weighing ≥ 60 kg.Continuation phase: 1 A + 1 B of Rifinah tablets for participants weighing ≤ 50 kg or less; and 2 B of Rifinah tablets for participants weighing \> 50 kg.\
**Control**\
The same drugs as separate formulations (N = 81).\
**Doses used**\
Intensive phase: daily isoniazid 300 mg and pyrazinamide 500 mg 3 times a day, regardless of body weight; rifampicin 450 mg for participants weighing ≤ 50 kg and 600 mg for participants weighing \> 50 kg.Continuation phase: the dose of isoniazid and rifampicin were the same as for the intensive phase.\
In both cases (FDCs and single‐drug formulations), drugs were administered daily, except pyracinamide during the intensive phase as separated formulation given 3 times a day. There were 3 kinds of treatment management (whole‐course hospitalization; outpatients treatment during the entire treatment course and hospitalization only during intensive phase), combined with 3 supervision models respectively (supervision by medical staff; supervision by non‐medical staff who had been trained by the medical staff (relatives, colleagues) and supervision by medical staff in the intensive phase but non‐medical staff in the continuation phase). Treatment and supervision was established according to participants economic statusOutcomes**Outcomes used in this review**\
Sputum conversion rate at 2 and 6 months after initiation of treatment.Compliance.Adverse events: those leading to discontinuation of therapy and other adverse events.Death.\
**Outcomes reported and not used in this review**\
Resolution of pulmonary lesion in chest radiography.Cavity closure rates in X‐rays at 6 months.Laboratory examination (blood routine, platelet, and urine routine).Notes**Location**: China\
**Trial setting**: hospital\
**Source of funding**: not mentioned\
**Comments**: follow‐up duration was to the EOT. Sputum smear and culture were examined each month during the 6 months of treatment. X‐ray was taken at 2 months and at EOT. Blood and urine tests were done every month, as for hepatic and renal function***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThere was insufficient information about random sequence generation process to permit a judgment of 'low risk' or 'high risk'.Allocation concealment (selection bias)Unclear riskThere was insufficient information to permit a judgement of 'low risk' or 'high risk\'.Blinding of participants and personnel (performance bias) All outcomesLow riskDue to difficulties in blinding the interventions for participants and personnel, when the trial did not provide specification of blinding methods, we considered it to be an open design. In addition, we judged that the outcomes were unlikely to have been influenced by lack of blinding (objective and measurable outcomes).Blinding of outcome assessment (detection bias) All outcomesLow riskNo blinding of outcome assessment, but the outcome measurement was unlikely to have been influenced by lack of blinding (objective and measurable outcomes).Incomplete outcome data (attrition bias) All outcomesHigh riskPotentially inappropriate application of simple imputation.Selective reporting (reporting bias)Unclear riskInsufficient information to permit judgement of 'low risk' or 'high risk'.Other biasLow riskThe trial appears to be free of other sources of bias.[^8]

Characteristics of excluded studies \[ordered by study ID\] {#CD009913-sec2-0020}
===========================================================

StudyReason for exclusion[@CD009913-bbs2-0015]Controlled clinical trial that compared FDCs versus single‐drug formulations for pulmonary TB, but with 2 different treatment regimens in intervention and control groups.[@CD009913-bbs2-0016]RCT that compared FDCs versus single‐drug formulations for pulmonary TB, but with 2 different treatment regimens in intervention and control groups.[@CD009913-bbs2-0017]RCT that compared 2 FDCs: Chinese fixed‐dose compounds (2FEISU/4FEINING regimen) with 2RIFANAH/4RIFINAH regimen for new smear positive pulmonary TB participants, presented as an abstract for the 9th Congress of the Asian Pacific Society of Respirology 10--13 December 2004, Hong Kong. Complete data were unavailable.[@CD009913-bbs2-0018]RCT that compared FDCs versus single‐drug formulations for pulmonary TB, but with 2 different treatment regimens in intervention and control groups.[@CD009913-bbs2-0019]RCT that compared 2 different regimens of treatment for pulmonary TB administered as single‐drug formulations.[@CD009913-bbs2-0020]Descriptive study of use of 4FDCs tablets for pulmonary TB.[@CD009913-bbs2-0021]RCT that compared FDCs versus single‐drug formulations for pulmonary TB, but with 2 different treatment regimens in intervention and control groups.[@CD009913-bbs2-0022]RCT that compared 2 different regimens for pulmonary TB.[@CD009913-bbs2-0023]RCT that compared FDCs versus single‐drug formulations for pulmonary TB, and was presented as a poster in the 12th Congress of the Asian Pacific Society of Respirology. Completed data were unavailable.[@CD009913-bbs2-0024]RCT that compared FDCs versus single‐drug formulations for pulmonary TB, but also included TB participants that were already treated.[@CD009913-bbs2-0025]RCT that met the inclusion criteria of this Cochrane review according to published protocol, but is not yet published. Data were unavailable.[@CD009913-bbs2-0026]Controlled clinical trial that compared FDCs versus single‐drug formulations for pulmonary TB, but had 2 different treatment regimens in intervention and control groups.[@CD009913-bbs2-0027]Descriptive study of methodological issue of unpublished RCTs (registration: ClinicalTrial.gov database: NCT00216385). Compared 4FDCs tablets versus 3FDCs + Gatifloxacin for pulmonary TB.[@CD009913-bbs2-0028]RCT that compared different treatment regimens (2Rifater/4Rifinah versus 2Rifater+E/6H+Thiacetazone) for untreated, sputum positive pulmonary TB.[@CD009913-bbs2-0029]RCT that compared FDCs versus single‐drug formulations for pulmonary TB, and was presented as a poster in the 12th Congress of the Asian Pacific Society of Respirology. Completed data were unavailable.[@CD009913-bbs2-0030]Study compared FDCs versus single‐drug formulations for pulmonary TB. It is unclear whether or not this is a clinical trial, as there is no mention of allocation or randomization.[@CD009913-bbs2-0031]RCT that compared FDCs versus single‐drug formulations, but with 2 different treatment regimens in intervention and control groups.[^9]

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD009913-sec2-0021}
======================================================================

[@CD009913-bbs2-0032]MethodsRandomized controlled trial (RCT)ParticipantsUnknownInterventionsFixed‐dose combinations (FDCs) versus \"Plate‐type combined drug\"OutcomesUnknownNotesWe identified this study through other sources, not through database searches. We did not find the Chinese article.[@CD009913-bbs2-0033]MethodsRCTParticipantsUnknownInterventionsFDCs versus \"Plate‐type combined drug\"OutcomesUnknownNotesWe identified this study through other sources, not through database searches. We did not find the Chinese article.[@CD009913-bbs2-0034]MethodsRCTParticipantsUnknownInterventionsFDCs versus single‐drug formulationsOutcomesUnknownNotesWe identified this study through other sources, not through database searches. We did not find the Chinese article.[@CD009913-bbs2-0035]MethodsRCTParticipantsUnknownInterventionsFDCs versus single‐drug formulationsOutcomesUnknownNotesWe identified this study through other sources, not through database searches. We did not find the Chinese article.[^10]

CRG, DRC, and XB conceived and designed the idea for this Cochrane review. All review authors contributed to the protocol development. CRG wrote the protocol ([@CD009913-bbs2-0063]).CRG, MR, and AVR extracted data from the included trials.CRG, AVR, and DRC assessed risk of bias in the included trials.CRG and MR entered data into RevMan ([@CD009913-bbs2-0050]).MR and CRG performed and interpreted the analyses.DRC drafted the \'Summary of findings\' tables.All review authors drafted the final review version and critically reviewed the content.CRG wrote the final review version.All review authors approved the final review version.

Internal sources {#CD009913-sec2-0017}
================

Cochrane Infectious Disease Group, UK.Liverpool School of Tropical Medicine, UK.

External sources {#CD009913-sec2-0018}
================

Department for International Development (DFID), UK.Grant: 5242

CRG has no known conflicts of interest. DRC has no known conflicts of interest. AVR has no known conflicts of interest. MR has no known conflicts of interest. LP has no known conflicts of interest. JC has no known conflicts of interest. XB has no known conflicts of interest.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^ We did not downgrade the quality of the evidence due to limitations in design and execution. Analysis of studies at low risk of bias does not change the effect estimate. ^2^Quality not downgraded for inconsistency (I² statistic = 0%). ^3^Quality not downgraded for indirectness. Differences in dosages probably do not affect the comparability of groups ^4^We downgraded by 1 for imprecision. The optimal information size considering an absolute \> 0.5% non‐inferiority margin as clinically meaningful, is not reached. In addition 1 side of the 95% CI does not exclude potential harm associated to FDCs. ^5^We downgraded by 1 for methodological limitations. Exclusion of studies at highest risk of bias heavily affects the pooled estimate of effect. ^6^Quality not downgraded for inconsistency (I² statistic = 26%). ^7^We downgraded by 1 for imprecision. The optimal information size considering an absolute \> 0.1% non‐inferiority margin as clinically meaningful, is not reached. ^8^Quality not downgraded for imprecision. Although the optimal information size (considering an absolute \> 0.5% non‐inferiority margin as clinically meaningful) is not reached, the total sample size and number of events are very large. ^9^Quality not downgraded for inconsistency. Studies of highest risk of bias contribute to explain the large heterogeneity (I² statistic = 57%).

[^3]: **Abbreviations:** EOT: end of treatment; TB: tuberculosis.

    ^1^[@CD009913-bbs2-0005] did not report the outcomes included in this table and [@CD009913-bbs2-0007] was not included in quantitative analysis. ^2^Outcomes reported in each clinical trial. ^3^Treatment failure was defined in the preliminary publication ([@CD009913-bbs2-0043]).

[^4]: **Abbreviations:** H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; S: streptomycin. ^1^In [@CD009913-bbs2-0004] and [@CD009913-bbs2-0006] the treatment regimen was 8 weeks for intensive phase and 18 weeks for continuation phase. ^2^Intensive phase: Regimen 1: 2SHRZ, Regimen 2: 1SHRZ or Regimen 3: 2HRZ and continuation phase: H and R to complete 6 months of treatment (4HR or 5HR).

[^5]: **Abbreviations:** kg: kilograms of body weight; H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; FDCs: fixed‐dose combinations; SDF: single‐dose formulations; mg: milligrams; DOT: directly‐observed treatment.

    ^1^In [@CD009913-bbs2-0004] the treatment regimen was 8 weeks for intensive phase and 18 weeks for continuation phase. ^2^In [@CD009913-bbs2-0006] the treatment regimen was 8 weeks for intensive phase and 18 weeks for continuation phase. ^3^ Data and dosage simulation done only for the groups 1 and 3. (In [@CD009913-bbs2-0007] there were another two regimens for the intensive phase: 2 and 4). ^4^Data extracted and dose simulation done only for the regimen 1: 2SHRZ. (In [@CD009913-bbs2-0010] there were another two regimens for the intensive phase: 1SHRZ and 2HRZ). ^5^In the FDCs group, data and dosage similation presented for the regimen A. (In [@CD009913-bbs2-0012] there was another FDCs regimen: regimen B). ^6^In [@CD009913-bbs2-0014] there were 3 modes of treatment supervision.

[^6]: ^1^We did not downgrade the quality due to inconsistency. I² statistic = 0%. ^2^We did not downgrade the quality for risk of bias. There were no limitations in the design and execution of the trials. ^3^Downgraded by 1 for imprecision. The optimal information size, considering an absolute \> 0.5% non‐inferiority margin as clinically meaningful, is not reached. In addition, 1 side of the 95% CI does not exclude potential harm associated to FDCs. ^4^We did not downgrade quality for indirectness. Differences in dosages probably do not affect the comparability of groups. ^5^We did not downgrade quality due to inconsistency. Large heterogeneity (I² statistic = 72%) can be explained by the limited number of events and the effect of chance. ^6^Downgraded by 1 for imprecision. The optimal information size, considering an absolute \> 0.1% non‐inferiority margin as clinically meaningful, is not reached. In addition, the number of events is very limited. ^7^We did not downgrade the quality due to inconsistency. There was only a single included trial. ^8^We did not downgrade the quality due to imprecision. Although the optimal information size considering an absolute \> 0.5% non‐inferiority margin as clinically meaningful is not reached, the total sample size and number of events are very large.

[^7]: ^1^We based all calculations are based on: 1‐sided tests, with a ratio of 1:1, power of 0.9, and confidence level of 0.05. ^2^We performed all calculations using: http://www.sealedenvelope.com/power/binary‐noninferior/. ^3^ If there is truly no difference between the standard and experimental treatment, then 737,340 participants are required to be 90% sure that the upper limit of a 1‐sided 95% confidence interval (CI) (or equivalently a 90% 2‐sided CI) will exclude a difference in favour of the standard group of more than 0.1%.

[^8]: **Abbreviations:** RCT: randomized controlled trial; TB: tuberculosis; AFB: acid‐fast bacilli; kg: kilograms of body weight; HIV: human immunodeficiency virus; FDCs: fixed‐dose combinations; H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; mg: milligrams; WHO: World Health Organization; ITT: intention‐to‐treat; S: streptomycin; DOT: directly observed treatment; USA: United States of America; SD: standard deviation; EOT: end of treatment.

[^9]: **Abbreviations:** FDCs: fixed‐dose combinations; TB: tuberculosis; RCT: randomized controlled trial.

[^10]: **Abbreviations:** RCT: randomized controlled trial; FDCs: fixed‐dose combinations.
